All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000007-18 | A Multicentre, Randomised, Double-Blind, Parallel Group, 24 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/250mcg with Salmeterol 50mcg Bot... | bad-data | |
| Reported results | 2004-000060-27 | A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 700mg BID plus ritonavir 100mg BID Versus Lopinavir/ritonavir 400mg/100mg BID when Administered in... | 2007-11-27 | due-trials |
| Reported results | 2004-000091-14 | A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for... | 2005-12-07 | due-trials |
| Completed, but no date, and reported results | 2004-000106-41 | A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis | bad-data | |
| Completed, but no date, and reported results Terminated | 2004-000336-81 | GW433908 Expanded Access Program for HIV infected subjects non responding or intolerant to the previous antiretroviral treatments | bad-data | |
| Reported results | 2004-000367-98 | A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor... | 2007-01-31 | due-trials |
| Reported results | 2004-000368-28 | A Double-blind, Randomised, Multicentre, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-4971... | 2007-02-28 | due-trials |
| Reported results | 2004-000369-37 | A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjuncti... | 2005-12-16 | due-trials |
| Reported results | 2004-000370-31 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antago... | 2005-08-08 | due-trials |
| Reported results | 2004-000371-34 | A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 Wh... | 2006-01-18 | due-trials |
| Reported results | 2004-000374-31 | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Sub... | 2006-07-21 | due-trials |
| Reported results | 2004-000406-51 | A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S... | 2007-05-31 | due-trials |
| Reported results | 2004-000482-35 | A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthrit... | 2006-12-08 | due-trials |
| Reported results | 2004-000518-37 | A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals? HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a... | 2009-01-20 | due-trials |
| Reported results | 2004-000576-13 | A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthm... | 2005-10-28 | due-trials |
| Reported results | 2004-000610-39 | A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism following Total Knee Replacement Surgery. | 2006-09-15 | due-trials |
| Reported results | 2004-000754-24 | An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-inf... | 2006-05-22 | due-trials |
| Completed, but no date, and reported results | 2004-000784-97 | A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily, versus Oral Cephalexin, ... | bad-data | |
| Reported results | 2004-000789-11 | A 12-week, randomised, double-blind, placebo-controlled, parallel-group multicentre study to evaluate the anti-inflammatory activity of GW842470 4mg twice daily on pulmonary hyperinflation in patients... | 2005-09-15 | due-trials |
| Completed, but no date | 2004-000805-23 | A national, multicentric, randomised, controlled trial. Applications of a critical pathway using LEVOFLOXACIN for the management of patients with abnormal PSA | bad-data | |
| Reported results | 2004-000848-24 | An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome | 2005-07-21 | due-trials |
| Reported results | 2004-000882-36 | A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein... | 2006-07-17 | due-trials |
| Completed, but no date, and reported results | 2004-000929-30 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase III Study to Evaluate Corticosteroid-reduction and -sparing Effects of Mepolizumab 750 mg Intravenous in Subjects with... | bad-data | |
| Completed, but no date, and reported results | 2004-000930-35 | An open-label extension study to Study 100185 to evaluate long-term saftey, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome. | bad-data | |
| Reported results | 2004-000985-12 | An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease. | 2006-04-10 | due-trials |
| Reported results | 2004-001020-20 | A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antogonist, GW679769, when adminis... | 2006-01-05 | due-trials |
| Reported results | 2004-001021-22 | A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg a... | 2006-06-09 | due-trials |
| Reported results | 2004-001173-26 | A phase III, double-blind, randomized study to assess the consistency of the immunogenicity of three consecutive production lots of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered... | 2009-01-06 | due-trials |
| Reported results | 2004-001175-19 | A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live attenuated... | 2006-10-08 | due-trials |
| Completed, but no date, and reported results | 2004-001182-18 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunct... | bad-data | |
| No trial status on register, and reported results | 2004-001223-37 | Ensayo clínico abierto en fase IV, para evaluar la inmunogenicidad y reactogenicidad de la vacuna combinada DTPa (Infanrix) de GlaxoSmithKline Biologicals administrada como dosis de recuerdo a los 4 a... | bad-data | |
| Reported results | 2004-001249-14 | A Phase III open, multicentre, booster vaccination study to assess the immunogenicity, safety and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b-m... | 2005-03-17 | due-trials |
| Reported results | 2004-001325-14 | Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatitis ... | 2009-11-26 | due-trials |
| Reported results | 2004-001456-36 | A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer. Studio di fase... | 2010-02-18 | due-trials |
| Reported results | 2004-001469-16 | A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor ag... | 2006-10-20 | due-trials |
| Completed, but no date, and reported results | 2004-001549-13 | A pilot, randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of Vardenafil versus placebo administered 12, 18 and 24 hours prior to initiation of sexual in... | bad-data | |
| Reported results | 2004-001680-22 | A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole CR 1-24mg administered once daily for 12 weeks in subje... | 2005-07-01 | due-trials |
| Reported results | 2004-001814-14 | A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunctio... | 2007-04-09 | due-trials |
| Completed, but no date, and reported results | 2004-001823-39 | An open, randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as... | bad-data | |
| Reported results | 2004-001894-24 | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients wi... | 2005-09-19 | due-trials |
| Reported results | 2004-001905-93 | A Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer | 2006-11-01 | due-trials |
| Reported results | 2004-001906-29 | Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in patients with relapsed or refractory inflammatory breast cancer | 2010-05-31 | due-trials |
| Completed, but no date, and reported results | 2004-001999-40 | A randomised, multicentre, double-blind, placebo-controlled, 2-arm, Phase III study of oral GW572016 in combination with paclitaxel in subjects previously untreated for advanced or metastatic breast c... | bad-data | |
| Completed, but no date, and reported results | 2004-002362-37 | A multicentre, randomised, double-blind, placebo-controlled, dose ascending, four way crossover study to examine efficacy (FEV1),safety, tolerability, pharmacodynamics and pharmacokinetics of single ... | bad-data | |
| Reported results | 2004-002605-77 | A Proof-of-Principle Study to Evaluate a Combination Therapy for the Treatment of Migraine | 2005-05-16 | due-trials |
| Reported results | 2004-002676-41 | Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals live attenuated varicella vaccine (VarilrixTM) given on a... | 2016-12-15 | due-trials |
| Reported results | 2004-002769-18 | A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steadystate pharmacokinetics of SB-681323 7.5 mg per day in patients with ... | 2006-03-02 | due-trials |
| Reported results | 2004-002872-41 | A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis | 2007-05-06 | due-trials |
| Reported results | 2004-002873-21 | A study to assess disease pathology and key therapeutic targets in severe asthma | 2012-05-21 | due-trials |
| Reported results | 2004-003619-22 | A placebo-controlled study to investigate the efficacy of a combination analgesic treatment compared to its individual components in primary dysmenorrhoea. | 2005-06-23 | due-trials |
| Reported results | 2004-003768-32 | A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Bio... | 2006-03-03 | due-trials |
| Reported results | 2004-003769-33 | A phase III open (partially double-blind), controlled, multicenter, multicountry primary & booster vaccination study to demonstrate the non-inferiority of the meningococcal serogroup C response of Gla... | 2006-07-13 | due-trials |
| Completed, but no date, and reported results | 2004-003803-19 | A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochlor... | bad-data | |
| Reported results | 2004-003827-10 | A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinav... | 2007-04-30 | due-trials |
| Reported results | 2004-003865-33 | A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regimens... | 2007-09-16 | due-trials |
| Reported results | 2004-003866-13 | A Phase IIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in... | 2006-07-23 | due-trials |
| Completed, but no date, and reported results Terminated | 2004-003928-35 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Meta... | bad-data | |
| Reported results | 2004-004090-29 | A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 D... | 2008-08-15 | due-trials |
| Reported results | 2004-004193-91 | A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45m... | 2006-07-21 | due-trials |
| Reported results | 2004-004247-22 | A 28-day, Randomised, Double-Blind, Active Comparator, Controlled Study to Assess the Effects of Rosiglitazone, Inhaled Corticosteroid, Theophylline and Theophylline Plus Inhaled Corticosteroid on Inf... | 2007-06-06 | due-trials |
| Completed, but no date, and reported results | 2004-004248-37 | A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulat... | bad-data | |
| Completed, but no date, and reported results | 2004-004342-41 | A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures | bad-data | |
| Reported results | 2004-004343-21 | A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures | 2008-05-13 | due-trials |
| Reported results | 2004-004370-85 | A phase III, multicentric open study to evaluate the immunological memory induced by a 3-dose primary vaccination followed by a booster dose with GSK Biologicals’ 11-valent conjugate pneumococcal vacc... | 2005-04-18 | due-trials |
| Completed, but no date, and reported results | 2004-004371-11 | A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children... | bad-data | |
| Reported results | 2004-004378-10 | Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed followin... | 2014-02-11 | due-trials |
| Completed, but no date, and reported results Terminated | 2004-004406-24 | A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1 SB-275833 Ointment versus Placebo Ointment Applied Twice Daily ... | bad-data | |
| Reported results | 2004-004409-24 | A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg-3... | 2005-10-20 | due-trials |
| Completed, but no date, and reported results | 2004-004434-14 | A randomised, double-blind, placebo controlled, parallel group, multicentre two week study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aquenous nasal spra... | bad-data | |
| Reported results | 2004-004439-70 | A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusi... | 2005-09-09 | due-trials |
| Reported results | 2004-004743-22 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg f... | 2006-01-16 | due-trials |
| Reported results | 2004-004744-43 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg f... | 2005-12-30 | due-trials |
| Reported results | 2004-004745-18 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg an... | 2005-11-23 | due-trials |
| Reported results | 2004-004749-17 | A randomized, double-blind, placebo-controlled, 2-week crossover, knemometric assessment of the effect of once daily GW685698X Aqueous Nasal Spray 100 mcg on short term growth in children ages 6 - 11 ... | 2006-01-31 | due-trials |
| Reported results | 2004-004984-32 | A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressiv... | 2006-09-27 | due-trials |
| Reported results | 2004-005024-40 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIABET... | 2005-02-17 | due-trials |
| Reported results | 2004-005058-30 | A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 500µg of GW799943X administered once-daily in the morning, 500µg of GW799943X administered ... | 2006-04-06 | due-trials |
| Reported results | 2004-005115-29 | A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship | 2006-08-03 | due-trials |
| Reported results | 2004-005123-18 | A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-... | 2005-11-22 | due-trials |
| Reported results | 2004-005213-11 | A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acut... | 2006-06-01 | due-trials |
| Completed, but no date, and reported results | 2004-005262-20 | A phase IV, single-blinded, randomized, single centre study to demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, Engerix-B in multidose presentation t... | bad-data | |
| Completed, but no date, and reported results | 2004-005263-19 | A phase III, blinded, randomised, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-O... | bad-data | |
| Reported results | 2005-000149-12 | A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, ... | 2005-12-01 | due-trials |
| Reported results | 2005-000158-61 | A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and ... | 2006-09-14 | due-trials |
| Reported results | 2005-000184-25 | A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release XR Tablets Compared with Ropinirole Immediate R... | 2006-12-15 | due-trials |
| Reported results | 2005-000374-48 | A randomized, open label comparative study to determine the proportion of asthma patients on Seretide Diskus 50/250 mcg b.i.d. achieving total control when given medication and compli-ance enhancement... | 2007-05-29 | due-trials |
| Completed, but no date, and reported results | 2005-000449-12 | A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attennu... | bad-data | |
| Reported results | 2005-000836-25 | Seretide vs Flixotide in mild persistent asthma (GINAII) | 2007-07-29 | due-trials |
| Exempt, with results | 2005-000846-35 | GlaxoSmithKline Study EGF100161 – An open-label, multicenter, 2 Part, Phase I/II dose escalation study of oral lapatinib in combination with docetaxel (Taxotere) plus trastuzumab (Herceptin) in subjec... | 2022-06-22 | not-yet-due |
| Reported results | 2005-000848-83 | Teilverblindete, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Wirksamkeit von Dickextrakt aus Kürbissamen (Kürbissamen-Extrakt) und Kürbissamen bei Patienten mit benigner Prostatah... | 2009-10-28 | due-trials |
| Reported results | 2005-000867-24 | A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION WI... | 2007-05-10 | due-trials |
| Reported results | 2005-000902-30 | A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients | 2006-12-04 | due-trials |
| Completed, but no date, and reported results | 2005-000965-21 | A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulat... | bad-data | |
| Reported results | 2005-000979-18 | A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with mi... | 2006-12-11 | due-trials |
| Reported results | 2005-000995-41 | A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibrosis ... | 2008-02-29 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-001010-41 | An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 in patients with Fibromyalgia syndrome comorbid ... | bad-data | |
| Reported results Terminated | 2005-001122-87 | A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg, 400mcg, 600mcg and 800mcg Administered Once ... | 2006-01-13 | due-trials |
| Completed, but no date, and reported results | 2005-001123-11 | A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 25mcg, 50mcg, 100mcg, and 200mcg Administered Once D... | bad-data | |
| Completed, but no date, and reported results | 2005-001124-36 | A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 100mcg, 200mcg, 300mcg and 400mcg Administered Once ... | bad-data | |
| Reported results | 2005-001150-24 | A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Comp... | 2007-09-11 | due-trials |
| Reported results | 2005-001246-16 | A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimiz... | 2007-06-27 | due-trials |
| Reported results | 2005-001247-39 | A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimis... | 2007-10-23 | due-trials |
| Reported results | 2005-001256-20 | A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 250mg, 375mg an... | 2006-12-28 | due-trials |
| Reported results | 2005-001288-73 | A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Bio... | 2008-02-13 | due-trials |
| Reported results | 2005-001335-30 | A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up t... | 2007-09-11 | due-trials |
| Reported results | 2005-001384-60 | An exploratory, observational cohort study investigating commercially available treatments which may reduce the scab stage of recurrent herpes labialis | 2005-11-29 | due-trials |
| Reported results | 2005-001555-38 | Open Immunization Study to Determine the Reactogenicity and Immunogenicity of Fluarix/ Influsplit SSW 2005/2006 in Persons as of 18 Years of Age | 2005-08-08 | due-trials |
| Reported results | 2005-001556-20 | Integrated Biomarker and Imaging Study – 2 (IBIS-2) | 2007-08-28 | due-trials |
| Reported results | 2005-001558-26 | A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR 24 WEE... | 2007-06-25 | due-trials |
| Reported results | 2005-001667-58 | A phase III, double-blind, randomized study to assess the consistency of the immunogenicity of three consecutive production lots of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered ... | 2007-03-01 | due-trials |
| Reported results | 2005-001723-10 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opio... | 2006-05-26 | due-trials |
| Reported results | 2005-001724-37 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opio... | 2006-06-29 | due-trials |
| Reported results | 2005-001725-28 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfun... | 2007-02-16 | due-trials |
| Completed, but no date, and reported results | 2005-001771-35 | Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Centre, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous... | bad-data | |
| Reported results | 2005-001841-40 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg Twice-Daily, GW685698X Inhalation Powder 200... | 2012-11-27 | due-trials |
| Exempt, with results | 2005-001928-37 | A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate vaccine containing the adjuvant AS25 (FluAS25) in... | not-yet-due | |
| Reported results | 2005-001974-28 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunct... | 2006-05-09 | due-trials |
| Reported results | 2005-001977-82 | A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing... | 2007-12-19 | due-trials |
| Reported results | 2005-002044-26 | A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults | 2006-05-31 | due-trials |
| Reported results | 2005-002212-13 | A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma | 2013-09-10 | due-trials |
| Reported results | 2005-002219-26 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive... | 2006-10-19 | due-trials |
| Completed, but no date, and reported results | 2005-002261-37 | A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of Radafaxine Extended-Release (100-140mg/day) Compar... | bad-data | |
| Trial is outside EEC, and reported results | 2005-002352-18 | A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of sa... | bad-data | |
| Exempt, with results | 2005-002360-28 | An open, randomized phase I/II study to demonstrate the non inferiority in term of cellular mediated immune response between GlaxoSmithKline Biologicals influenza candidate vaccines containing various... | not-yet-due | |
| Reported results | 2005-002485-11 | A Randomized, Single Blind, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck | 2007-12-27 | due-trials |
| Reported results | 2005-002546-20 | A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly accor... | 2014-01-29 | due-trials |
| Reported results | 2005-002883-27 | A multi-centre, double blind, double-dummy, placebo-controlled, randomised, adaptive, dose-range study to evaluate the dafety and efficacy of SB-773812 administered once daily for 12 weeks in adults w... | 2008-06-28 | due-trials |
| Reported results | 2005-002949-40 | A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination SERETIDE at a dose of 50/100mcg twice daily and fluticasone ... | 2006-10-27 | due-trials |
| Reported results | 2005-002950-23 | A multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for ‘Total control’ results in better airway hyper-responsivenes... | 2007-08-27 | due-trials |
| Reported results | 2005-002969-37 | A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. | 2006-11-18 | due-trials |
| Reported results | 2005-002976-14 | A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of eit... | 2007-10-15 | due-trials |
| Reported results | 2005-002978-30 | A double-blind, randomized, placebo-controlled, repeat dose study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 with GW869682 in subjects with type 2 diabetes... | 2006-05-24 | due-trials |
| Completed, but no date, and reported results | 2005-003052-36 | A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a ... | bad-data | |
| Completed, but no date, and reported results | 2005-003299-40 | A phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunizatio... | bad-data | |
| Reported results | 2005-003300-11 | A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal... | 2006-06-28 | due-trials |
| Reported results | 2005-003319-64 | A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects | 2007-12-18 | due-trials |
| Reported results | 2005-003400-11 | A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Comp... | 2008-06-24 | due-trials |
| Reported results | 2005-003401-87 | A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 ... | 2008-12-03 | due-trials |
| Reported results | 2005-003432-22 | A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women w... | 2019-10-21 | due-trials |
| Reported results | 2005-003437-41 | An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to... | 2007-01-17 | due-trials |
| Reported results | 2005-003590-24 | Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de determinación de dosis óptima de SB-480848, un inhibidor de la fosfolipasa A2 asociada a lipoproteínas... | 2007-09-27 | due-trials |
| Reported results | 2005-003767-23 | A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subj... | 2014-01-21 | due-trials |
| Reported results | 2005-003926-24 | "Estudio fase 3, aleatorizado, abierto, multicéntrico, de lapatinib en combinación con trastuzumab vs lapatinib en monoterapia en sujetos con cáncer de mama metastásico cuyo tumor ha progresado durant... | 2010-10-29 | due-trials |
| Reported results | 2005-003944-68 | A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy | 2018-03-15 | due-trials |
| Completed, but no date, and reported results | 2005-003945-16 | An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients | bad-data | |
| Reported results | 2005-004078-25 | A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Me... | 2014-12-29 | due-trials |
| Reported results | 2005-004285-16 | A 28-day, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 (7.5 mg) in subjects with coron... | 2007-08-08 | due-trials |
| Reported results | 2005-004350-28 | A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Me... | 2015-03-17 | due-trials |
| Reported results | 2005-004419-31 | A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and ... | 2007-01-11 | due-trials |
| Reported results | 2005-004434-40 | A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatmen... | 2006-08-18 | due-trials |
| Reported results | 2005-004480-37 | A single blind, placebo controlled, multi-centre study to investigate the pharmacokinetics, safety, tolerability and pharmacodynamics of the TRPV1 antagonist SB-705498 against the pain of acute migrai... | 2006-08-22 | due-trials |
| Reported results | 2005-004481-16 | A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth ... | 2007-10-02 | due-trials |
| Reported results | 2005-004493-25 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg fo... | 2006-06-23 | due-trials |
| Exempt, with results | 2005-004497-24 | Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccines M72/AS01B and M72/AS02A when ... | not-yet-due | |
| Reported results | 2005-004517-14 | Open study to determine the immunogenicity and reactogenicity of Influsplit SSW 2005/2006 in children from 6 years until 13 years of age | 2006-04-20 | due-trials |
| Reported results | 2005-004889-17 | A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 (10mg and 30 mg) on polysomnograph sleep recordings, subjective sleep asse... | 2007-07-13 | due-trials |
| Reported results | 2005-005089-34 | A double-blind, randomised, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition in subjects wi... | 2008-06-20 | due-trials |
| Reported results | 2005-005186-10 | A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer | 2013-08-05 | due-trials |
| Reported results | 2005-005307-42 | An evaluation of the 4 mg nicotine mint lozenge for the relief of cognitive impairment associated with nicotine withdrawal. | 2006-04-20 | due-trials |
| Reported results | 2005-005329-68 | A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat ... | 2007-01-24 | due-trials |
| Reported results | 2005-005336-27 | The INPACT study Improving with Nadroparin the Prognosis in Advanced Cancer Treatment - A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in pa... | 2009-09-07 | due-trials |
| Reported results | 2005-005339-83 | A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmatic ... | 2007-06-20 | due-trials |
| Reported results | 2005-005340-12 | A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in sub... | 2006-05-22 | due-trials |
| Reported results | 2005-005372-32 | A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound fo... | 2008-09-11 | due-trials |
| Reported results | 2005-005421-59 | A phase III, open, randomized, controlled, multicentre, primary & booster study to demonstrate the non-inferiority of the MenC & Hib immune responses of GSK Biologicals’ Hib-MenC vaccine co-administer... | 2007-06-07 | due-trials |
| Reported results | 2005-005423-34 | A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR T... | 2007-08-29 | due-trials |
| Reported results | 2005-005430-12 | Randomised, double-blind, placebo-controlled study of topical GW842470X formulation in adult patients with moderate atopic dermatitis | 2006-11-18 | due-trials |
| Reported results | 2005-005431-97 | An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabe... | 2007-03-07 | due-trials |
| Reported results | 2005-005602-23 | Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol ... | 2007-02-13 | due-trials |
| Exempt, with results | 2005-005682-11 | A phase I/II, randomized, observer blinded study to evaluate and compare the safety, reactogenicity and immunogenicity of various formulations of the GlaxoSmithKline Biologicals’ adjuvanted 11-valent ... | 2007-09-18 | not-yet-due |
| Reported results | 2005-005703-42 | A 12 week, randomised, double blind study evaluating the effects of low dose (10mg) and high dose (80mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by Ultra smal... | 2007-08-28 | due-trials |
| Completed, but no date, and reported results | 2005-005825-75 | A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and GSK... | bad-data | |
| Reported results | 2005-005855-16 | A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Pr... | 2006-07-13 | due-trials |
| Reported results | 2005-005856-42 | A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention ... | 2006-07-11 | due-trials |
| Exempt, with results | 2005-005943-24 | A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a... | 2007-06-19 | not-yet-due |
| Completed, but no date, and reported results | 2005-005944-22 | Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined measles... | bad-data | |
| Reported results | 2005-006065-14 | A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and GSK B... | 2006-11-24 | due-trials |
| Trial is outside EEC, and reported results | 2005-006066-34 | A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-teta... | bad-data | |
| Reported results | 2005-006074-10 | A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) ... | 2008-11-25 | due-trials |
| Reported results | 2005-006118-17 | A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome | 2007-06-14 | due-trials |
| Reported results | 2005-006163-31 | A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz... | 2012-06-06 | due-trials |
| Reported results | 2006-000143-26 | A Phase II, Non-randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib GW786034 as Pre-Surgical Therapy in Treatment-Na ve Subjects with Stage IA or IB, Resectable Non Small ... | 2008-04-07 | due-trials |
| Reported results | 2006-000215-22 | A randomised, double blind, placebo controlled, two-way crossover, three phase, study, to investigate the trial models, Vienna Challenge Chamber, in and out of season, and Park Study in season and the... | 2006-11-20 | due-trials |
| Reported results | 2006-000236-27 | A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO... | 2011-07-28 | due-trials |
| Reported results | 2006-000253-21 | Reaching asthma control with salmeterol/fluticasone 50 / 250µg bd combination in steroid naive or low dose JCS patients by using the asthma control test (ACT) as measurement. | 2007-09-14 | due-trials |
| Exempt, with results | 2006-000442-39 | An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ 11PCV combined with adjuvant AS02V given as a 2-dose vaccination in adults aged 18-40 years old. | 2006-10-06 | not-yet-due |
| Reported results | 2006-000468-95 | A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's Disease | 2007-06-12 | due-trials |
| Reported results | 2006-000470-78 | A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered... | 2008-07-18 | due-trials |
| Reported results | 2006-000471-14 | EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag s... | 2015-07-06 | due-trials |
| Completed, but no date, and reported results | 2006-000518-19 | A Phase III, open, multicentre study to assess the long-term persistence of a booster dose of GSK Biologicals? Hib-MenC conjugate vaccine compared to a booster dose of Infanrix? hexa (combined diphthe... | bad-data | |
| Reported results | 2006-000549-20 | An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 7 to 9 years o... | 2006-12-14 | due-trials |
| Reported results | 2006-000553-22 | An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 4-6 years old,... | 2006-11-27 | due-trials |
| Reported results | 2006-000554-46 | A phase II, observer-blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DSSITGDPa-HBV-IPV/Hib vaccine containing diphtheri... | 2007-05-31 | due-trials |
| Reported results | 2006-000556-41 | An open, phase IV, single-group multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in children at 4-5 ye... | 2007-05-14 | due-trials |
| Trial is outside EEC, and reported results | 2006-000557-21 | A phase IIIb randomized, double-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine compared ... | bad-data | |
| Reported results | 2006-000558-30 | A phase IIIb randomised, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administe... | 2007-10-24 | due-trials |
| Reported results | 2006-000559-16 | A phase IIIb randomized, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GlaxoSmithKline (GS... | 2007-04-10 | due-trials |
| Reported results | 2006-000560-93 | A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal conjug... | 2006-12-08 | due-trials |
| Reported results | 2006-000562-36 | ''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer'' | 2021-07-01 | due-trials |
| Reported results | 2006-000564-81 | A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer | 2019-12-23 | due-trials |
| Reported results | 2006-000635-94 | A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or plac... | 2006-06-15 | due-trials |
| Reported results | 2006-000729-70 | A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability, pharmacodynamics and steady-state pharmacokinetics of repeated doses of GW856553 in patients with COPD... | 2007-12-20 | due-trials |
| Reported results | 2006-000781-37 | A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist... | 2017-08-24 | due-trials |
| Reported results Terminated | 2006-000923-32 | A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous inf... | 2009-10-29 | due-trials |
| Reported results | 2006-000939-97 | A phase IIb, controlled, randomised, multicenter, single blind study to demonstrate the Non-Inferiority of the low dose influenza vaccine with or without adjuvant AS03 compared with Fluarix™ (GlaxoSmi... | 2006-12-19 | due-trials |
| Reported results | 2006-000956-42 | A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302) | 2018-06-21 | due-trials |
| Reported results | 2006-001072-21 | A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma | 2008-08-11 | due-trials |
| Reported results | 2006-001168-22 | A phase II, randomized, open, partially controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvant... | 2009-12-04 | due-trials |
| Reported results | 2006-001169-40 | A phase IIb, controlled, randomised, multicenter, observer blinded study to demonstrate the lot-to-lot consistency of three consecutive production lots of low dose of influenza vaccine adjuvanted with... | 2006-12-18 | due-trials |
| Reported results | 2006-001234-40 | Estudio aleatorizado, doble ciego, controlado con placebo para investigar la seguridad, tolerabilidad y actividad clínica de dosis orales repetidas de 7,5 mg de GW856553 dos veces al día durante 28 d... | 2008-01-21 | due-trials |
| Reported results | 2006-001275-38 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study To Evaluate Efficacy, Safety And Tolerability Of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg Once ... | 2007-04-27 | due-trials |
| Reported results Terminated | 2006-001276-20 | A randomized, open-label, multicenter, parallel-group study to compare the efficacy, safety and resource utilization of a remifentanil/propofol analgosedation regimen versus a sufentanyl/propofol anal... | 2007-06-14 | due-trials |
| Exempt, with results | 2006-001278-26 | Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma | 2010-07-05 | not-yet-due |
| Reported results | 2006-001281-16 | A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (split virus formulation containi... | 2007-07-31 | due-trials |
| Reported results | 2006-001402-92 | A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhib... | 2009-03-24 | due-trials |
| Reported results | 2006-001403-11 | A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone extended release tablets as adjunctive therapy to donepezil on cognition and... | 2009-01-28 | due-trials |
| Reported results | 2006-001417-16 | A randomized, double-blind, double-dummy, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticason... | 2008-01-28 | due-trials |
| Reported results | 2006-001419-30 | A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705... | 2007-04-03 | due-trials |
| Reported results | 2006-001433-17 | A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are ref... | 2013-05-23 | due-trials |
| Reported results | 2006-001481-17 | A phase IIIb, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant booster administration of GlaxoSmithKline (GSK) B... | 2009-02-17 | due-trials |
| Reported results | 2006-001482-42 | A phase IIIb open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when given as a catch-up im... | 2008-08-27 | due-trials |
| Reported results | 2006-001623-18 | A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P... | 2013-11-15 | due-trials |
| Reported results | 2006-001628-38 | A phase IIIa single-blind, controlled multicentre study to assess the safety, reactogenicity and immunogenicity of GSK Biologicals 10-valent pneumococcal conjugate vaccine or Prevenar when given as a ... | 2007-11-06 | due-trials |
| Reported results | 2006-001839-21 | CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION. | 2012-06-21 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-001877-13 | A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator paroxe... | bad-data | |
| Completed, but no date, and reported results Terminated | 2006-001891-19 | A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetic... | bad-data | |
| Reported results | 2006-001907-13 | LETROZOLE versus LETROZOLE PLUS LAPATINIB GW572016 IN HORMONE-SENSITIVE, HER-2 NEGATIVE OPERABLE BREAST CANCER. A DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH BIOMARKER EVALUATION | 2011-04-09 | due-trials |
| Reported results | 2006-001918-33 | A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influspit SSW®) 2006/2007 in people aged 18 years or above | 2006-08-28 | due-trials |
| Reported results | 2006-001934-42 | A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjugate ... | 2007-08-13 | due-trials |
| Reported results | 2006-002033-21 | A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, ... | 2017-10-09 | due-trials |
| Reported results | 2006-002038-39 | A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and ... | 2008-10-01 | due-trials |
| Reported results | 2006-002074-22 | A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer. | 2013-09-18 | due-trials |
| Listed as ongoing, but also has a completion date | 2006-002080-93 | An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer | 2015-05-31 | bad-data |
| Reported results | 2006-002088-18 | An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy. | 2008-01-02 | due-trials |
| Reported results | 2006-002095-18 | A phase II randomized, double-blind (observer blind), adjuvant justification study of RTS,S/AS01B and RTS,S/AS02A, candidate malaria vaccines, administered according to a 0, 1, 2 months schedule in ma... | 2007-07-13 | due-trials |
| Reported results | 2006-002139-26 | An open label, repeat dose, dose escalation study conducted in RLS patients to characterize pharmacokinetics and food effect of ropinirole controlled release for RLS | 2006-12-12 | due-trials |
| Reported results Terminated | 2006-002157-79 | “A Multi-Center, Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus” | 2006-12-18 | due-trials |
| Reported results | 2006-002381-18 | An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192 | 2013-12-20 | due-trials |
| Reported results | 2006-002407-14 | Eptifibatide Versus Abciximab in primary PCI for Acute ST elevation Myocardial Infarction (EVA-AMI) | 2007-12-04 | due-trials |
| Reported results | 2006-002632-21 | A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal ... | 2007-02-22 | due-trials |
| Reported results | 2006-002633-20 | Estudio aleatorizado, doble-ciego, controlado con placebo, de grupos paralelos, de definición de dosis, para investigar la eficacia mediante RM y la seguridad de la administración de firategrast (150 ... | 2010-05-27 | due-trials |
| Completed, but no date, and reported results | 2006-002680-18 | A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmith... | bad-data | |
| Reported results | 2006-002691-18 | A multi-centre, randomised, single-blind, placebo-controlled, parallel group study to investigate the efficacy of single pre-emptive doses of GW842166X, a non-cannabinoid CB2 receptor agonist, on pain... | 2007-03-29 | due-trials |
| Reported results | 2006-002703-13 | A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-... | 2009-02-13 | due-trials |
| Reported results | 2006-002704-34 | A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-... | 2008-10-17 | due-trials |
| Reported results | 2006-002839-24 | A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly... | 2007-06-07 | due-trials |
| Reported results | 2006-002897-23 | An observational study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with GSK Biologicals... | 2007-06-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-002898-47 | A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa... | 2008-05-02 | bad-data |
| Reported results | 2006-002911-28 | A multicentre, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of once daily oral dosing of GW501516 (2.5 mg, 5 mg an... | 2006-06-15 | due-trials |
| Reported results | 2006-002943-10 | REPEAT. Repeated ExPosure To Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura. An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic ... | 2008-06-24 | due-trials |
| Reported results | 2006-002945-36 | LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase... | 2013-03-07 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-002946-13 | A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoieti... | 2014-02-03 | bad-data |
| Completed, but no date, and reported results Terminated | 2006-003023-37 | A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce the Risk of Acute U... | bad-data | |
| Completed, but no date, and reported results | 2006-003236-30 | A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vaccin... | bad-data | |
| Completed, but no date, and reported results | 2006-003237-32 | A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vaccin... | bad-data | |
| Reported results | 2006-003238-14 | A phase II/III, observer-blind, multicountry, multicentre, randomized study to demonstrate the superiority in terms of immunogenicity of AS25 adjuvanted influenza vaccine administered in adults aged 5... | 2007-06-14 | due-trials |
| Reported results | 2006-003239-61 | A phase III, randomised study to evaluate the clinical consistency in terms of immunogenicity and reactogenicity of three production lots of the liquid formulation of GlaxoSmithKline (GSK) Biologicals... | 2007-08-24 | due-trials |
| Reported results | 2006-003295-36 | Randomised double-blind, placebo-controlled, cross-over study comparing the effects of single dose and repeated dosing treatment for 14 days of vestipitant / paroxetine combination in an enriched popu... | 2009-08-06 | due-trials |
| Reported results | 2006-003374-10 | An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Sk... | 2008-09-26 | due-trials |
| Reported results | 2006-003500-19 | A multi-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-way crossover, incomplete block design study to investigate the efficacy, safety, tolerability, pharmacodynamics and pharm... | 2007-05-31 | due-trials |
| Reported results | 2006-003597-10 | Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) | 2007-08-30 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-003602-26 | A double-blind, two-period, placebo controlled cross-over study of the effects of the CB2 agonist GW842166 on pain and sensitisation in patients with osteoarthritis. | bad-data | |
| Reported results | 2006-003762-33 | A phase IIIb, double blind, randomised, placebo?controlled, multi?country, multicentre study to assess the safety, reactogenicity and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals? ... | 2008-03-31 | due-trials |
| Completed, but no date, and reported results | 2006-003769-15 | A phase II, controlled, randomized, single centre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of AS03 adjuvant co... | bad-data | |
| Exempt, with results | 2006-003796-12 | A Phase I-II partially-blinded, randomized, dose- ranging study (10-30-90 mcg) to compare the safety and immunogenicity of GSK Biologicals’ candidate HIV vaccine F4co (p24-RT-Nef-p17), adjuvanted or n... | not-yet-due | |
| Reported results | 2006-003807-38 | A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals? HPV-16/18 L1 AS04 vaccine co-administered with GlaxoSmithKline Biologicals? ... | 2008-07-25 | due-trials |
| Reported results | 2006-003815-31 | A phase IIb, controlled, randomized, multicenter, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvante... | 2007-02-05 | due-trials |
| Exempt, with results | 2006-004014-41 | A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776A in patients wi... | 2011-05-30 | not-yet-due |
| Reported results | 2006-004033-15 | A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400mcg... | 2007-05-10 | due-trials |
| Reported results | 2006-004041-42 | A phase II, randomised, open study to evaluate the immunogenicity and safety of a single or double-dose of the pandemic influenza candidate vaccine split virus formulation adjuvanted with AS03 gi... | 2008-03-05 | due-trials |
| Reported results | 2006-004152-20 | A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-m... | 2009-05-30 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-004204-39 | A randomized, open label, multicentre study to compare the pharmaco-economic implications of an analgesia based regimen with remifentanil and a conventional sedation based regimen using propofol in me... | bad-data | |
| Reported results | 2006-004212-48 | Estudio doble ciego, aleatorizado, controlado con placebo y alprazolam, de diseño cruzado con tres periodos y bloques incompletos, para comparar mediante Resonancia Magnética Funcional, las posibles ... | 2008-01-10 | due-trials |
| Reported results | 2006-004236-70 | A phase IIb, open, randomized, controlled primary vaccination study to evaluate the non-inferiority and the persistence of the immune response of GSK Biologicals’ meningococcal serogroup ACWY conjugat... | 2007-12-03 | due-trials |
| Reported results | 2006-004694-97 | A Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment Naive Subjects. | 2008-02-07 | due-trials |
| Reported results | 2006-004695-12 | A Dose-Ranging Study of GSK189075 versus Placebo in the treatment of Type 2 Diabetes Mellitus in Subjects taking Metformin. | 2006-11-23 | due-trials |
| Reported results | 2006-004774-27 | An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatmen... | 2009-07-31 | due-trials |
| Reported results | 2006-004777-10 | A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant chemo(-radio)therapy, to patients with MAGE-A... | 2013-08-08 | due-trials |
| Reported results | 2006-004790-10 | A Proof-of-Principle Analgesic Adjuvant Pilot Study in Post-Operative Dental Pain | 2008-09-16 | due-trials |
| Reported results | 2006-004863-69 | A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of gE... | 2014-07-14 | due-trials |
| Reported results | 2006-004946-17 | ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess t... | 2011-04-08 | due-trials |
| Reported results Terminated | 2006-005078-28 | A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5). | 2009-02-12 | due-trials |
| Reported results | 2006-005177-21 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibo... | 2010-03-04 | due-trials |
| Reported results | 2006-005227-42 | A double-blind, placebo-controlled, parallel study to evaluate the effects of GW-856553 on endothelial function/ vascular compliance in subjects with dyslipidaemia. | 2008-04-23 | due-trials |
| Reported results | 2006-005228-18 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the Mor... | 2007-09-06 | due-trials |
| Reported results | 2006-005477-22 | A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H5N1... | 2008-10-20 | due-trials |
| Reported results Terminated | 2006-005578-39 | A randomised, double-blind, placebo-controlled study to explore the antidepressant properties of the P38a kinase inhibitor GW856553X 15mg compared to placebo in subjects with Major Depressive Disorder... | 2008-06-30 | due-trials |
| Reported results | 2006-005579-16 | Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Subjects | 2008-08-01 | due-trials |
| Reported results | 2006-005733-38 | A phase III, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when given as a b... | 2008-06-14 | due-trials |
| Reported results | 2006-005807-32 | A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and the pharm... | 2011-06-16 | due-trials |
| No trial status on register, and reported results | 2006-005891-41 | A phase IIIb, observer-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when g... | bad-data | |
| Reported results | 2006-005912-28 | A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy | 2010-03-17 | due-trials |
| Reported results | 2006-005914-10 | A Multicentre, Randomised, Double-blind, Placebo and Naproxen (500mg) BID controlled, Phase II Proof of Concept, Parallel Group Study to Assess the Efficacy and Safety of Oral GW842166 at Two Dose Lev... | 2007-08-14 | due-trials |
| Reported results | 2006-005953-31 | Inhibition of Dental Plaque Regrowth by an Ethanol-Free 0,2% Chlorhexidine Mouth Rinsing Solution | 2007-08-24 | due-trials |
| Reported results | 2006-005998-21 | A multicentre randomised, double-blind, parallel-group study to compare the salmeterol xinafoate/fluticasone propionate combination (Seretide® Diskus® 50/100) 50/100 micrograms one inhalation twice da... | 2007-03-21 | due-trials |
| Reported results | 2006-005999-41 | A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vac... | 2008-04-28 | due-trials |
| Reported results | 2006-006000-11 | An 8 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in the Vienna Challenge Chamber in subjects with seasonal allergic rh... | 2008-02-04 | due-trials |
| Reported results | 2006-006015-72 | Estudio CR9108963: Estudio de búsqueda de dosis optima de SB-751689 en mujeres posmenopáusicas con osteoporosis | 2008-12-26 | due-trials |
| Reported results | 2006-006083-33 | A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses o... | 2007-10-11 | due-trials |
| Reported results | 2006-006209-94 | An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets... | 2007-08-29 | due-trials |
| Exempt, with results | 2006-006240-63 | A study to assess the pharmacokinetics of single escalating doses of inhaled GSK961081 DPI (a dual pharmacophore) in healthy subjects (Part 1) and a randomised, double-blind, double dummy, crossover (... | 2008-05-23 | not-yet-due |
| Reported results | 2006-006460-32 | A phase IV, open, multicenter, multicountry study to assess the long-term antibody persistence of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal ser... | 2010-05-18 | due-trials |
| Reported results | 2006-006537-40 | A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer | 2011-12-20 | due-trials |
| Reported results | 2006-006552-36 | A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination... | 2007-08-08 | due-trials |
| Reported results | 2006-006580-23 | Immunogenicity & safety study of GSK Biologicals’ meningococcal vaccine GSK134612 when co-administered with GSK Biologicals’ MMRV vaccine (Priorix-Tetra™) in healthy 12 to 23-month-old children. | 2008-03-26 | due-trials |
| Reported results | 2006-006680-23 | A phase III, open, randomized, controlled study to demonstrate the immunogenicity, reactogenicity and safety of GSK Biologicals meningococcal serogroup ACWY conjugate vaccine (GSK134612, MenACWY-TT) c... | 2008-10-27 | due-trials |
| Reported results | 2006-006710-15 | A randomised, single blind, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR) | 2007-05-16 | due-trials |
| Reported results | 2006-007057-42 | An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast | 2010-02-12 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-000097-23 | Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of in... | bad-data | |
| Completed, but no date, and reported results | 2007-000115-28 | A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adul... | bad-data | |
| Exempt, with results | 2007-000164-24 | A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered in... | not-yet-due | |
| Reported results | 2007-000187-25 | A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses o... | 2007-10-15 | due-trials |
| Reported results | 2007-000243-10 | An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previous... | 2013-05-21 | due-trials |
| Reported results | 2007-000244-27 | An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with CHOP, in patients with previously untreated Follicular Lymp... | 2014-03-07 | due-trials |
| Completed, but no date, and reported results | 2007-000261-38 | A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biolog... | bad-data | |
| Reported results | 2007-000292-42 | ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess t... | 2011-08-23 | due-trials |
| Reported results | 2007-000454-31 | Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects | 2009-11-26 | due-trials |
| Reported results | 2007-000493-23 | A Comparison of Two Analgesic Products for the Treatment of Headache | 2007-11-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-000548-29 | A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg OD versus Montelu... | 2007-10-31 | bad-data |
| Reported results | 2007-000596-42 | A phase III open study to assess the safety, reactogenicity and immunogenicity following booster administration of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine, co-admin... | 2009-03-30 | due-trials |
| Reported results | 2007-000683-24 | Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in ... | 2008-04-29 | due-trials |
| Reported results Terminated | 2007-000779-40 | A Phase II Trial of Pazopanib, a Pan Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor, in Relapsed or Refractory Small Cell Lung Cancer (SCLC) | 2008-09-29 | due-trials |
| Ongoing | 2007-000838-39 | A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2007-000929-22 | A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol response... | bad-data | |
| Reported results | 2007-001167-29 | A phase IIIb multi-centre, open, controlled study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal serogroup ... | 2008-12-30 | due-trials |
| Reported results | 2007-001283-73 | A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAG... | 2014-09-23 | due-trials |
| Reported results | 2007-001295-36 | A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 adm... | 2008-07-30 | due-trials |
| Reported results | 2007-001345-18 | A 19-week, randomized, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate 50/100mcg BID, fluticasone propionate 100mcg BID... | 2008-07-23 | due-trials |
| Reported results | 2007-001391-37 | A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics o... | 2007-11-09 | due-trials |
| Reported results | 2007-001463-29 | A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects | 2008-06-05 | due-trials |
| Reported results | 2007-001477-29 | A proof-of-concept study of SB-751689 in male and female subjects with a fractured distal radius. | 2008-11-20 | due-trials |
| Reported results | 2007-001703-38 | A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemica... | 2011-03-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-001713-42 | A randomised, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolesce... | 2008-09-10 | bad-data |
| Reported results | 2007-001731-55 | A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the prev... | 2014-12-17 | due-trials |
| Reported results | 2007-001828-12 | A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ (Influsplit SSW®) 2007/2008 injected intramuscularly in young adults (18 to 60 years... | 2007-07-11 | due-trials |
| Reported results | 2007-002155-17 | A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv... | 2011-12-20 | due-trials |
| Reported results | 2007-002221-76 | An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in children ag... | 2007-12-31 | due-trials |
| Reported results | 2007-002368-83 | A phase III, observer-blind, multicountry, multicenter, study to evaluate the safety, reactogenicity and immunogenicity, of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine administered i... | 2008-04-06 | due-trials |
| Completed, but no date, and reported results | 2007-002374-55 | Simultaneous fMRI/EEG of the 4 mg nicotine lozenge in relief of cognitive impairment associated with nicotine withdrawal | bad-data | |
| Reported results Terminated | 2007-002472-34 | A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer | 2009-06-30 | due-trials |
| Exempt, with results | 2007-002777-32 | A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’ HP... | 2013-03-18 | not-yet-due |
| Completed, but no date, and reported results | 2007-002783-10 | A phase II, controlled, single centre, open study to evaluate the safety, reactogenicity and immunogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with a reduced dose o... | bad-data | |
| Completed, but no date, and reported results | 2007-002880-29 | A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥66 years) previo... | bad-data | |
| Completed, but no date, and reported results | 2007-002881-36 | A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥67 years) previo... | bad-data | |
| Exempt, with results | 2007-002918-19 | A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors | 2008-04-15 | not-yet-due |
| Reported results | 2007-002950-42 | A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a... | 2015-07-15 | due-trials |
| Reported results | 2007-002951-18 | A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a... | 2013-07-15 | due-trials |
| Reported results | 2007-003248-31 | An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced an... | 2008-04-30 | due-trials |
| Reported results | 2007-003256-11 | A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alternativ... | 2009-07-27 | due-trials |
| Reported results | 2007-003290-29 | A phase II, observer-blind, multicountry, multicentre, randomized study to demonstrate the non-Inferiority of GlaxoSmithKline Biologicals’ one-container AS25 adjuvanted influenza vaccine compared to G... | 2007-11-02 | due-trials |
| Reported results | 2007-003477-94 | A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellular... | 2008-07-08 | due-trials |
| Reported results | 2007-003597-25 | A 12-month open-label, randomized parallel-group study to investigate the influence of salmeterol/fluticasone either in fixed combination (SFC500/50 µg bid) or seperately (SAL 50 µg and FP 500 µg bid)... | 2009-06-25 | due-trials |
| Reported results | 2007-003776-18 | A phase II, controlled, randomized, multicentre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of the AS03 adjuvant ... | 2008-05-08 | due-trials |
| Reported results | 2007-003802-86 | A phase II, observer-blind, multicountry, multicentre, randomized study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ influenza vaccine adjuvanted with ... | 2008-06-10 | due-trials |
| Reported results | 2007-004002-26 | A phase III randomized, single-blind, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine with Pediacel™ versus co-ad... | 2010-12-01 | due-trials |
| Reported results Terminated | 2007-004025-20 | A randomised, double-blind, parallel-group, fixed-dose, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo and Paroxetine in participa... | 2007-11-29 | due-trials |
| Reported results | 2007-004033-42 | A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD). | 2009-10-02 | due-trials |
| Reported results | 2007-004035-35 | A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment a... | 2008-05-07 | due-trials |
| Reported results | 2007-004117-33 | A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selectiv... | 2009-06-16 | due-trials |
| Reported results | 2007-004190-26 | An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant | 2014-08-19 | due-trials |
| Reported results | 2007-004223-38 | A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients | 2011-10-26 | due-trials |
| Reported results | 2007-004347-30 | A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biologica... | 2009-04-28 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-004442-32 | A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticaso... | 2008-10-02 | bad-data |
| Reported results | 2007-004458-98 | A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticason... | 2008-09-20 | due-trials |
| Reported results | 2007-004459-13 | A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticaso... | 2008-11-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-004568-27 | A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer | 2022-07-27 | bad-data |
| Reported results | 2007-004797-79 | A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms | 2007-11-24 | due-trials |
| Reported results | 2007-004807-37 | Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD | 2008-10-24 | due-trials |
| Reported results | 2007-004878-31 | An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibo... | 2013-03-19 | due-trials |
| Reported results | 2007-005082-34 | A Proof of Principle Study to Investigate the Efficacy of a Medical Device and Topical Analgesic Combination for the Treatment of Pain and Performance Related Function in Osteoarthritis | 2008-06-12 | due-trials |
| Reported results | 2007-005148-26 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent... | 2011-03-17 | due-trials |
| Reported results | 2007-005153-32 | A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAPATUMUMAB ( [HGS1012], A FULLY HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH CARBOPLATIN AND... | 2012-03-29 | due-trials |
| Reported results | 2007-005169-36 | A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin-Induced Nausea and Vomiting | 2009-04-13 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-005203-18 | An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanom... | bad-data | |
| Reported results | 2007-005301-22 | An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis... | 2008-05-26 | due-trials |
| Reported results | 2007-005302-44 | A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhin... | 2008-05-21 | due-trials |
| Reported results | 2007-005338-35 | A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT imagi... | 2009-12-03 | due-trials |
| Reported results | 2007-005343-16 | A phase II, open, study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine when administered as a booster dose to children aged 16-... | 2008-08-18 | due-trials |
| Reported results | 2007-005353-28 | A randomised, double-blind, evaluation of the effects of paracetamol on the BOLD fMRI response to painful stimuli in subjects with osteoarthritis. Estudio doble-ciego, aleatorizado para evaluar los e... | 2011-08-17 | due-trials |
| Reported results | 2007-005392-34 | A phase III long-term follow-up study to assess antibody persistence and immunological memory in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination... | 2011-11-21 | due-trials |
| Reported results | 2007-005486-34 | A Pilot Study to Evaluate the Relative Bioavailability of Diclofenac as Measured by Microdialysis After Repeated Doses of Two Topical Diclofenac Formulations | 2008-07-21 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-005520-32 | An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis. | bad-data | |
| Ongoing | 2007-005725-29 | A PHASE III STUDY OF ERBB2 POSITIVE ADVANCED OR METASTATIC GASTRIC OR ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA TREATED WITH CAPECITABINE PLUS OXALIPLATIN WITH OR WITHOUT LAPATINIB A... | not-yet-due | |
| Reported results | 2007-005791-14 | A randomised, placebo-controlled, incomplete block, three-way cross-over study to evaluate the effect of treatment with repeat inhaled doses of GW870086X on the allergen-induced early and late asthmat... | 2009-11-03 | due-trials |
| Reported results | 2007-005851-40 | A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chro... | 2009-11-03 | due-trials |
| Reported results | 2007-005954-22 | A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus plac... | 2008-07-10 | due-trials |
| Reported results | 2007-006073-84 | A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with cho... | 2009-01-27 | due-trials |
| Reported results | 2007-006287-29 | Dose ranging study for GSK233705B delivered once daily in subjects with COPD. | 2009-02-06 | due-trials |
| Reported results | 2007-006562-15 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg ... | 2008-06-30 | due-trials |
| Reported results Terminated | 2007-006651-39 | A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly ... | 2009-05-05 | due-trials |
| Reported results | 2007-007043-27 | A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals’ thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biol... | 2008-04-11 | due-trials |
| Reported results | 2007-007648-85 | A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Pr... | 2016-12-09 | due-trials |
| Reported results | 2007-007783-14 | A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmithKl... | 2010-01-08 | due-trials |
| Reported results | 2007-007837-38 | A phase III, open, randomized, controlled, primary vaccination study to demonstrate non-inferiority of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY conjugate vaccine compared to lic... | 2009-01-08 | due-trials |
| Reported results | 2007-007876-41 | A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals’ H... | 2009-06-18 | due-trials |
| Reported results | 2008-000367-42 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccin... | 2015-07-27 | due-trials |
| Completed, but no date, and reported results | 2008-000369-44 | A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vacc... | bad-data | |
| Reported results | 2008-000406-36 | A randomised, double-blind, double-dummy, placebo-controlled, 3-way crossover study to evaluate potential next-day residual effects of a single evening dose of 3mg eszopiclone and 7.5mg zopiclone in h... | 2008-10-30 | due-trials |
| Reported results | 2008-000526-39 | A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different m... | 2008-11-03 | due-trials |
| Reported results | 2008-000660-17 | TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible t... | 2013-02-28 | due-trials |
| Reported results | 2008-000673-38 | A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic B... | 2018-03-22 | due-trials |
| Reported results | 2008-000725-18 | A randomised, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamo... | 2008-10-19 | due-trials |
| Reported results | 2008-000727-26 | Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) | 2009-02-25 | due-trials |
| Reported results | 2008-000789-22 | SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation. An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Effic... | 2011-09-06 | due-trials |
| Reported results | 2008-000826-37 | Study AZ3110865, a study comparing SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease | 2010-03-09 | due-trials |
| Reported results | 2008-000827-25 | Estudio AZ3110866: Estudio de dosis fija de SB-742457 frente a placebo, como tratamiento añadido a donepezilo, en sujetos con enfermedad de Alzheimer leve a moderada | 2010-11-16 | due-trials |
| Reported results | 2008-000872-25 | A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals’ adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscula... | 2010-12-09 | due-trials |
| Reported results | 2008-001095-77 | A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 formula... | 2009-08-10 | due-trials |
| Completed, but no date, and reported results | 2008-001301-42 | An open Phase II study to assess the clinical activity and safety of recMAGE-A3 + AS15 cancer immunotherapeutic in patients with metastatic cutaneous melanoma, and to explore its immunogenic propertie... | bad-data | |
| Exempt, with results | 2008-001303-34 | A phase I/II, randomized, single blind, controlled study in adults aged 18-60 years to evaluate the immunogenicity, safety and reactogenicity of an adjuvanted influenza vaccine candidate (GSK 2115160A... | 2009-01-28 | not-yet-due |
| Reported results | 2008-001307-33 | A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. | 2012-11-28 | due-trials |
| Reported results | 2008-001310-24 | A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2008/2009 injected intramuscularly in young adults (18 to 60 years... | 2008-07-30 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-001445-26 | A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thio... | bad-data | |
| Reported results | 2008-001507-39 | A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia who progr... | 2013-06-20 | due-trials |
| Reported results | 2008-001567-10 | A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber i... | 2008-08-28 | due-trials |
| Exempt, with results | 2008-001918-25 | An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and progres... | 2014-11-17 | not-yet-due |
| Exempt, with results | 2008-002046-27 | Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate | 2011-04-22 | not-yet-due |
| Reported results | 2008-002101-39 | An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration | 2009-09-09 | due-trials |
| Reported results | 2008-002102-19 | Estudio de pazopanib frente a sunitinib en el tratamiento de sujetos con carcinoma de células renales localmente avanzado y/o metastásico a Study of Pazopanib versus Sunitinib in the Treatment of Sub... | 2021-03-24 | due-trials |
| Reported results | 2008-002144-42 | A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage... | 2011-03-01 | due-trials |
| Reported results | 2008-002205-40 | DEFEND-1: Durable Response Therapy Evaluation For Early Or New Onset Type 1 Diabetes | 2012-01-31 | due-trials |
| Reported results | 2008-002301-38 | A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA™ on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus | 2010-09-17 | due-trials |
| Reported results | 2008-002360-33 | A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adu... | 2009-05-23 | due-trials |
| Reported results | 2008-002362-66 | A phase III, observer-blind, multi-country, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals FLU NG vaccine compared to the reference v... | 2009-12-15 | due-trials |
| Reported results | 2008-002447-16 | A double-blind placebo-controlled Phase III study to assess the efficacy of MAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma | 2016-03-15 | due-trials |
| Reported results | 2008-002580-13 | A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma | 2009-09-11 | due-trials |
| Reported results | 2008-002747-16 | FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high ... | 2010-05-11 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-003318-81 | A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine and Baxter’s Neisseri... | bad-data | |
| Reported results | 2008-003395-22 | The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition | 2009-07-22 | due-trials |
| Reported results | 2008-003741-87 | A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered ... | 2010-12-09 | due-trials |
| Reported results | 2008-003772-21 | A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY TO INVESTIGATE THE USE OF MEPOLIZUMAB (SB-240563) IN REDUCING THE NEED FOR SURGERY IN SUBJECTS WITH SEVERE BILATERAL NASAL POLYPOSIS | 2014-12-05 | due-trials |
| Reported results | 2008-003824-51 | A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2 years, 3 years and 4 years after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococca... | 2012-09-10 | due-trials |
| Reported results | 2008-003950-14 | A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn... | 2009-07-02 | due-trials |
| Reported results | 2008-004007-64 | An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma | 2015-04-01 | due-trials |
| Reported results | 2008-004092-22 | A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and ... | 2008-11-27 | due-trials |
| Reported results | 2008-004149-27 | A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma | 2010-08-01 | due-trials |
| Reported results | 2008-004177-17 | A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux... | 2019-01-22 | due-trials |
| Reported results | 2008-004181-10 | (FONDACAST, del inglés FONDAparinux in patients with a plaster CAST) Estudio Fase III, multicéntrico, aleatorizado, abierto, controlado, de dos grupos paralelos para evaluar la eficacia y seguridad de... | 2011-07-04 | due-trials |
| Reported results | 2008-004455-29 | A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination with ... | 2011-07-14 | due-trials |
| Reported results | 2008-004672-50 | A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or ... | 2017-08-24 | due-trials |
| Reported results | 2008-004711-35 | Estudio de vacunación, fase III, observador ciego, aleatorizado (3:3:2), control activo, multinacional, multicéntrico para evaluar la respuesta inmune celular y humoral de la vacuna FLU NG de GSK Biol... | 2009-12-04 | due-trials |
| Reported results | 2008-004866-15 | A Longitudinal MRI Study of Changes in Regional Body Composition During Orlistat (60mg)-Assisted Dieting | 2009-08-28 | due-trials |
| Reported results | 2008-004932-19 | A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia | 2018-05-17 | due-trials |
| Reported results | 2008-004933-99 | Study PXN110527: The investigation of the efficacy and pharmacokinetics of XP13512 in subjects with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had an inadequate response t... | 2009-07-27 | due-trials |
| Reported results | 2008-005030-73 | Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People W... | 2013-07-26 | due-trials |
| Reported results | 2008-005041-33 | A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke. | 2011-01-31 | due-trials |
| Reported results | 2008-005053-38 | An open-label study to investigate the pharmacodynamics of a repeat dose regimen of bevacizumab (10mg/kg q2w) and escalating repeat doses of pazopanib in renal cell carcinoma | 2013-11-01 | due-trials |
| Reported results | 2008-005120-86 | A phase II, observer-blind, randomised, placebo-controlled, adjuvant-dose selection, multicenter prophylactic vaccination study to evaluate the immunogenicity and safety of GSK Biologicals’ herpes zos... | 2010-07-02 | due-trials |
| Reported results | 2008-005149-48 | A phase III/IV, cluster-randomized, controlled study to evaluate the effectiveness of GlaxoSmithKline Biologicals’ 10-valent pneumococcal and non-typeable Haemophilus influenzae protein D conjugate va... | 2013-10-05 | due-trials |
| Reported results | 2008-005205-19 | A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthm... | 2009-07-28 | due-trials |
| Reported results Terminated | 2008-005288-33 | Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound | 2009-10-29 | due-trials |
| Completed, but no date, and reported results | 2008-005319-16 | ``A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejacula... | bad-data | |
| Reported results | 2008-005575-96 | A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) | 2013-10-17 | due-trials |
| Reported results | 2008-005811-16 | A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia | 2017-10-25 | due-trials |
| Reported results | 2008-006083-11 | An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinate... | 2014-07-18 | due-trials |
| Completed, but no date, and reported results | 2008-006124-64 | A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals dTpa-IPV vaccine (Boostrix Polio) compared with Sano... | bad-data | |
| Reported results | 2008-006345-72 | A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients. | 2009-09-21 | due-trials |
| Reported results | 2008-006365-91 | A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given in healthy infants at 3, 5 ... | 2009-06-25 | due-trials |
| Reported results | 2008-006551-51 | A phase III double-blind, cluster-randomized, controlled study to evaluate the impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals’ 10-valent pneumococc... | 2011-12-22 | due-trials |
| Reported results | 2008-006768-13 | Follow-up survey for comparing stable dosing with a symptom based “as needed-regimen” in moderate and severe persitent asthma. | 2010-04-22 | due-trials |
| Reported results | 2008-006986-10 | A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms | 2009-03-31 | due-trials |
| Reported results Terminated | 2008-007244-33 | The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils | 2010-06-02 | due-trials |
| Reported results | 2008-007605-37 | A phase III, open, multicentre, extension study to assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ a... | 2009-10-09 | due-trials |
| Reported results | 2008-007660-41 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With ... | 2013-04-01 | due-trials |
| Reported results | 2008-007661-24 | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus | 2013-03-08 | due-trials |
| Reported results | 2008-007662-37 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metform... | 2013-01-18 | due-trials |
| Reported results | 2008-007664-42 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepi... | 2013-04-02 | due-trials |
| Reported results | 2008-007846-69 | Estudio en fase III, abierto, multicéntrico para evaluar la persistencia de anticuerpos a a largo plazo en niños hasta los 6 años de edad, tras una pauta completa de vacunación (primaria y de recuerdo... | 2012-11-21 | due-trials |
| Reported results | 2008-008104-41 | A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), thr... | 2010-10-27 | due-trials |
| Reported results | 2008-008124-33 | A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant... | 2014-01-20 | due-trials |
| Reported results | 2008-008175-34 | A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor Agon... | 2010-11-19 | due-trials |
| Reported results | 2008-008254-23 | A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics | 2009-12-18 | due-trials |
| Reported results | 2009-009256-20 | Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL | 2015-11-21 | due-trials |
| Reported results | 2009-009885-15 | A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer | 2016-03-01 | due-trials |
| Reported results | 2009-010091-17 | A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury | 2010-07-19 | due-trials |
| Reported results | 2009-010269-21 | A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects. | 2016-12-22 | due-trials |
| Reported results | 2009-010270-37 | A Phase IIb pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance | 2015-01-23 | due-trials |
| Reported results | 2009-010421-39 | A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura (ITP). | 2014-05-06 | due-trials |
| Exempt, with results | 2009-010571-24 | An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancer | 2012-10-25 | not-yet-due |
| Reported results | 2009-010615-32 | A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects ... | 2012-03-06 | due-trials |
| Reported results | 2009-010811-34 | A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 years) ... | 2009-07-08 | due-trials |
| Completed, but no date, and reported results | 2009-011022-33 | A phase II, double-blind study to evaluate the safety, reactogenicity and immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a boos... | bad-data | |
| Reported results | 2009-011051-51 | A phase III, double-blind, randomized study to demonstrate the non-inferiority of an aged lot of GlaxoSmithKline Biologicals' FLU NG vaccine in adults aged 65 years and above compared to a fresh lot o... | 2009-10-05 | due-trials |
| Reported results | 2009-011150-17 | AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension | 2014-09-11 | due-trials |
| Reported results | 2009-011200-39 | A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to p... | 2010-07-07 | due-trials |
| Reported results | 2009-011357-41 | A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the first ... | 2015-02-03 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-011418-68 | Pilotstudie zur Anwendung eines pflanzlichen Kombinationspräparats bei Frauen mit Reizblase ("Overactive Bladder"-Syndrom). (Translation: Pilot-Study with a herbal combination in women suffering from... | bad-data | |
| Reported results | 2009-011459-39 | A randomised, double-blind, placebo-controlled 4-period crossover study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000μg), oral GSK835726 (10mg) and cetirizine (10mg) in ... | 2009-08-14 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-011461-84 | A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once- Daily in Subjects with Asthma | 2011-09-15 | bad-data |
| Reported results | 2009-011608-51 | A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with M... | 2012-07-31 | due-trials |
| Reported results | 2009-011782-92 | A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously in healthy, p... | 2011-05-03 | due-trials |
| Completed, but no date, and reported results | 2009-011855-40 | A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double ... | bad-data | |
| Trial is partly outside EEC, and reported results | 2009-012054-20 | A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adole... | 2011-05-12 | bad-data |
| Reported results | 2009-012055-19 | "A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritis" | 2010-10-01 | due-trials |
| Reported results | 2009-012117-21 | An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in adolescents... | 2010-04-07 | due-trials |
| Reported results | 2009-012188-32 | A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adu... | 2010-10-27 | due-trials |
| Reported results | 2009-012202-39 | A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi... | 2012-04-02 | due-trials |
| Completed, but no date, and reported results | 2009-012204-42 | A randomized, double-blind, placebo-controlled, parallel group study to investigate the ability of GSK706769 to maintain clinical efficacy after withdrawal of Enbrel in patients with rheumatoid arthri... | bad-data | |
| Reported results | 2009-012219-16 | A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and reactogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, ace... | 2012-03-01 | due-trials |
| Completed, but no date, and reported results | 2009-012223-29 | A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV candi... | bad-data | |
| Reported results | 2009-012460-14 | A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediat... | 2012-08-26 | due-trials |
| Reported results | 2009-012518-39 | A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t... | 2018-06-26 | due-trials |
| Reported results | 2009-012581-32 | A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). (Short title: The Stabiliz... | 2014-04-24 | due-trials |
| Reported results | 2009-012614-48 | A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease. | 2010-11-08 | due-trials |
| Reported results | 2009-012701-19 | A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae protein containing vacci... | 2011-03-02 | due-trials |
| Reported results | 2009-012836-33 | A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy | 2019-08-23 | due-trials |
| Reported results | 2009-013063-19 | A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with... | 2011-10-31 | due-trials |
| Reported results | 2009-013064-40 | A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with... | 2011-10-17 | due-trials |
| Reported results | 2009-013065-25 | A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compar... | 2011-02-02 | due-trials |
| Reported results | 2009-013067-19 | A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compar... | 2011-03-08 | due-trials |
| Completed, but no date, and reported results | 2009-013710-27 | A phase III, observer-blind, randomized trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvan... | bad-data | |
| Reported results | 2009-013783-39 | Estudio fase II, aleatorizado, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna experimental adyuvada de gripe pandémica H1N1 administrada como primovacunación y booste... | 2010-11-24 | due-trials |
| Reported results | 2009-013785-52 | Estudio fase III, no aleatorizado, abierto para evaluar la seguridad e inmunogenicidad de la vacuna H1N1 adyuvada con AS03A administrada como primovacunación y booster en sujetos entre 3 y 17 años de ... | 2010-11-27 | due-trials |
| Completed, but no date, and reported results | 2009-013837-92 | A phase III, open, randomized, trial to evaluate the immunogenicity and safety of a single or two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuva... | bad-data | |
| Reported results | 2009-013931-39 | A phase II, observer-blind, randomized study to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with GSK Biologicals’ A/California/7/2009 (H1N1)v-like vaccine containing th... | 2010-09-23 | due-trials |
| Reported results | 2009-014249-10 | A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. | 2015-11-23 | due-trials |
| Completed, but no date, and reported results | 2009-014275-53 | An open, single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-028 (208127/021) in which healthy adults were vaccina... | bad-data | |
| Reported results | 2009-014415-12 | A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refrac... | 2012-03-23 | due-trials |
| Reported results | 2009-014419-11 | A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuva... | 2010-11-04 | due-trials |
| Completed, but no date, and reported results | 2009-014448-13 | A phase III, randomised, single-blind study to evaluate the immunogenicity and safety of sequential administration of a licensed seasonal trivalent vaccine and the pandemic H1N1 influenza candidate va... | bad-data | |
| Completed, but no date, and reported results | 2009-014449-96 | A phase II, observer-blind, randomized trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvant... | bad-data | |
| Reported results | 2009-014543-36 | A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD | 2010-03-11 | due-trials |
| Completed, but no date, and reported results | 2009-014853-33 | An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-032 (208127/022) in which healthy adults were vaccinate... | bad-data | |
| Reported results | 2009-014858-15 | A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Ad... | 2015-03-16 | due-trials |
| Reported results | 2009-015008-25 | A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted w... | 2010-04-30 | due-trials |
| Completed, but no date, and reported results | 2009-015011-41 | Phase III, non-randomised, open-label study to evaluate the safety and immunogenicity of a prime-boost schedule of the H1N1 candidate vaccine adjuvanted with AS03B administered to subjects aged 3 to 1... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2009-015014-22 | A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered... | 2010-07-16 | bad-data |
| Reported results | 2009-015106-19 | A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration | 2012-10-05 | due-trials |
| Reported results Terminated | 2009-015174-35 | A phase II, randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted pandemic H1N1 influenza candidate vaccine following a 0-28 day or 0-4 month vaccination schedule in... | 2010-03-25 | due-trials |
| Reported results | 2009-015297-36 | A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma | 2016-06-17 | due-trials |
| Reported results | 2009-015298-11 | A Phase III randomized, open-label Study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma. | 2016-09-16 | due-trials |
| Reported results | 2009-015386-30 | A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with th... | 2011-12-14 | due-trials |
| Reported results | 2009-015512-17 | Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS) | 2013-12-05 | due-trials |
| Reported results | 2009-015791-94 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine... | 2015-07-27 | due-trials |
| Reported results | 2009-015914-23 | Clinical efficacy of an experimental toothpaste | 2010-05-18 | due-trials |
| Reported results | 2009-015960-32 | A phase III, randomised, observer-blind, multicentre study to evaluate the immunogenicity and safety of a 2-dose vaccination with the new process manufactured adjuvanted pandemic H1N1 influenza candid... | 2011-01-14 | due-trials |
| Completed, but no date, and reported results | 2009-015997-36 | A phase III, double-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological non-inferiority of two manufacturing processes of the A/California/7/2009 (H1N1)v-like a... | bad-data | |
| Reported results | 2009-016012-21 | A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria, tetanus and acell... | 2012-05-08 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-016035-35 | An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed ... | 2015-02-13 | bad-data |
| Completed, but no date, and reported results | 2009-016078-33 | A phase III, observer-blind, randomised trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvan... | bad-data | |
| Reported results | 2009-016268-35 | A phase II, randomized, observer blind study to evaluate the safety and immunogenicity of three different vaccination schedules employing two formulations of the monovalent A/California/7/2009 (H1N1)v... | 2011-05-10 | due-trials |
| Reported results | 2009-016581-80 | A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the al... | 2010-10-12 | due-trials |
| Reported results | 2009-016635-36 | A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2, 4 ... | 2011-10-11 | due-trials |
| Exempt, with results | 2009-016636-13 | An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients wi... | 2016-12-19 | not-yet-due |
| Reported results | 2009-016663-11 | A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour an... | 2011-05-27 | due-trials |
| Reported results | 2009-016690-15 | A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD | 2010-07-05 | due-trials |
| Reported results | 2009-016841-24 | A phase IIIB open, multicountry, randomized, controlled study to demonstrate the non-inferiority of the immune response of GSK Biologicals’ meningococcal serogroup A, C, W-135 and Y conjugate vaccine ... | 2013-09-10 | due-trials |
| Completed, but no date, and reported results | 2009-016911-39 | An open, phase IV, multicentre, study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children aged 11-12 ye... | bad-data | |
| Reported results | 2009-017282-35 | A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects | 2017-09-20 | due-trials |
| Reported results | 2009-017376-25 | An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refrac... | 2013-04-27 | due-trials |
| Completed, but no date, and reported results | 2009-017477-38 | An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Everolim... | bad-data | |
| Reported results | 2009-017669-44 | A study of the Effects of Inhaled Fliticasone Furotate/GW642444 versus Placebo on HPA Axis of Adolescent and Adult Asthmatics. | 2010-09-24 | due-trials |
| Reported results | 2009-017744-14 | An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures | 2013-04-12 | due-trials |
| Exempt, with results | 2009-017809-11 | A phase I/IIa randomized, observer-blind, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals’ herpes zoster vaccine, gE/AS01B in comparison to place... | 2013-05-14 | not-yet-due |
| Reported results | 2009-017951-87 | A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen. | 2015-05-25 | due-trials |
| Exempt, with results | 2009-018097-64 | Long-term follow-up of study participants from GlaxoSmithKline (GSK) Biologicals’-sponsored clinical trials evaluating Human Immunodeficiency Virus vaccine [F4co (p24-RT-Nef-p17)/AS01B vaccine] (73246... | 2014-05-19 | not-yet-due |
| Reported results | 2010-018389-22 | A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared... | 2011-01-20 | due-trials |
| Exempt, with results | 2010-018392-22 | Estudio fase I, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna antigripal estacional trivalente (GSK2186877A) adyuvada con varias dosis de AS03, administrada en niños ... | 2010-12-13 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2010-018412-32 | A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant... | 2012-09-12 | bad-data |
| Reported results | 2010-018730-51 | A phase IIIb, open, multi-centre, controlled study to assess the long-term persistence of antibodies after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus-toxo... | 2014-05-17 | due-trials |
| Reported results | 2010-018738-27 | A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis | 2010-12-29 | due-trials |
| Reported results | 2010-018775-17 | DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes | 2012-03-31 | due-trials |
| Reported results | 2010-018780-42 | Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Releapsed After Rituximab-Containing Therapy | 2017-01-19 | due-trials |
| Reported results | 2010-019095-70 | A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Dai... | 2011-10-06 | due-trials |
| Reported results | 2010-019157-17 | Evaluation of the safety and tolerability of re-dosing with intravenous (IV)otelixizumab in adult subjects with newly diagnosed type 1 diabetes mellitus. | 2011-07-14 | due-trials |
| Reported results | 2010-019253-18 | A phase II, open-label, multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine as a booster dose in children aged 12 to 18 months, previously ... | 2010-12-03 | due-trials |
| Reported results Terminated | 2010-019390-15 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast ... | 2011-08-01 | due-trials |
| Reported results | 2010-019465-28 | A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on th... | 2011-05-31 | due-trials |
| Trial is outside EEC, and reported results | 2010-019466-81 | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100 mg, GSK2190915 300 mg, M... | bad-data | |
| Trial is partly outside EEC, and reported results | 2010-019547-19 | A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in pae... | 2019-04-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2010-019577-16 | A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-line... | 2022-06-06 | bad-data |
| Reported results | 2010-019578-34 | A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer | 2013-02-25 | due-trials |
| Reported results | 2010-019589-10 | A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmete... | 2011-07-27 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-019590-15 | HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalatio... | 2011-10-19 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-019594-14 | A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the t... | 2011-10-18 | bad-data |
| Completed, but no date, and reported results | 2010-019600-23 | A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2010/2011 injected intramuscularly in young adults (18 to 60 years... | bad-data | |
| Reported results | 2010-019690-15 | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus | 2011-09-27 | due-trials |
| Reported results | 2010-019695-76 | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared ... | 2011-12-22 | due-trials |
| Reported results | 2010-019730-27 | A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of two formulations of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae prot... | 2012-10-01 | due-trials |
| Reported results | 2010-019777-15 | A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Melli... | 2012-05-30 | due-trials |
| Reported results Terminated | 2010-019832-11 | An open-label study to evaluate the utility of the apoptosis imaging biomarker [18F]ML-10 to assess the response to chemotherapy in patients with non Hodgkin's lymphoma. | 2012-02-06 | due-trials |
| Exempt, with results Terminated | 2010-019909-42 | A double-blind, randomized, placebo-controlled, Phase I/II Study evaluating the safety, immunogenicity and clinical activity of neoadjuvant treatment with WT1-A10 + AS15 Antigen-Specific Cancer Immuno... | 2014-11-14 | not-yet-due |
| Completed, but no date, and reported results | 2010-019989-91 | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Exploratory Study to Evaluate the Effect of Adding GSK2190915 300mg Tablets ... | bad-data | |
| Trial is partly outside EEC, and reported results | 2010-020069-26 | A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy | 2013-08-28 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-020144-34 | A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in the treatment o... | 2012-01-16 | bad-data |
| Trial is outside EEC, and reported results | 2010-020154-33 | RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures(≥12 years old) and Subjects with Lennox-Gastaut Syndrome (≥12 years ... | bad-data | |
| Reported results Terminated | 2010-020157-13 | An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepat... | 2011-07-15 | due-trials |
| Reported results | 2010-020227-48 | A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6... | 2017-01-10 | due-trials |
| Reported results Terminated | 2010-020312-12 | A phase IIa, observer-blind, multi-country, multicentre, randomised study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ quadrivalent influenza vaccine (... | 2012-11-27 | due-trials |
| Completed, but no date, and reported results Terminated | 2010-020313-81 | A Phase IIIA, open, randomized study to assess immunogenicity and safety of Fluarix™/Influsplit SSW® 2010/2011 or Pandemrix™ vaccination in adults aged 18 years and above previously vaccinated with on... | bad-data | |
| Reported results | 2010-020330-26 | A phase IV, open label, randomized, multicountry study to evaluate immunogenicity and safety of GSK Biologicals' seasonal (2010-2011) influenza vaccine FluarixTM in children previously vaccinated with... | 2011-05-26 | due-trials |
| Reported results | 2010-020331-39 | A Phase IV, open label, randomized, monocentric study to evaluate immunogenicity and safety of GSK Biologicals' seasonal (2010-2011) influenza vaccine FluarixTM in adolescents previously vaccinated wi... | 2011-07-07 | due-trials |
| Reported results | 2010-020352-59 | A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III con... | 2012-09-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-020412-11 | A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powd... | 2011-08-26 | bad-data |
| Completed, but no date, and reported results | 2010-020798-17 | A Randomized, Multi-Center, Blinded, Placebo-Controlled Study of Mapatumumab ([HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination with Sorafenib as a First-Line Therapy in Subject... | bad-data | |
| Reported results | 2010-020826-17 | An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment | 2011-03-22 | due-trials |
| Reported results | 2010-020965-26 | A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre... | 2019-04-15 | due-trials |
| Reported results | 2010-020993-41 | A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease. | 2013-02-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-021032-34 | A phase III, double-blind, randomized study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine compared to GSK Biologicals’ trivalent influenza vaccine admin... | 2011-06-15 | bad-data |
| Reported results | 2010-021034-63 | A phase III randomized, partially-blind, controlled, multi-country, multi-centre study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine D-QI... | 2011-06-06 | due-trials |
| Reported results | 2010-021059-25 | A 12-Week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol (VI) Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared with Salmeterol/Fluticasone Propi... | 2011-10-19 | due-trials |
| Reported results | 2010-021073-36 | Estudio fase III, doble ciego aleatorizado para evaluar la inmunogenicidad y seguridad de la vacuna antigripal tetravalente de GSK Biologicals GSK2282512A (FLU Q-QIV) comparada con la vacuna antigripa... | 2011-08-17 | due-trials |
| Reported results | 2010-021356-26 | A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramuscul... | 2012-11-05 | due-trials |
| Exempt, with results | 2010-021569-58 | A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to he... | 2012-01-05 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2010-021572-29 | An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued tr... | 2022-06-09 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-021621-12 | A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamiv... | 2015-03-18 | bad-data |
| Reported results | 2010-021638-72 | A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (... | 2015-07-15 | due-trials |
| Reported results | 2010-021642-22 | A two part study to investigate the pharmacokinetics and pharmacodynamics of SB705498, a TRPV1 antagonist, in cough. Part A: an open label study in healthy subjects to determine the exposure to SB-705... | 2012-01-19 | due-trials |
| Reported results | 2010-021798-34 | To assess the subjective effect of two paracetamol preparations on the feeling of breathing in subjects with the common cold. | 2010-12-08 | due-trials |
| Reported results | 2010-021800-72 | A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD. Studio multicentrico per confrontare l'efficacia e... | 2012-04-24 | due-trials |
| Reported results | 2010-021802-39 | A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 with tiotropium over 24 weeks in subjects with COPD | 2012-04-10 | due-trials |
| Reported results | 2010-022111-19 | Comparative efficacy of DUODART tm plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naive men with moderately sympt... | 2014-01-16 | due-trials |
| Reported results | 2010-022248-19 | An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination in ... | 2013-06-20 | due-trials |
| Reported results | 2010-022279-77 | A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persi... | 2011-08-19 | due-trials |
| Reported results | 2010-022280-35 | A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis. | 2011-04-14 | due-trials |
| Reported results | 2010-022382-10 | A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn's Disease Studio ran... | 2013-09-04 | due-trials |
| Reported results | 2010-022383-12 | A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn's Disease Studio di 52 sett... | 2013-10-23 | due-trials |
| Reported results | 2010-022384-35 | An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn's Disease Studio di estensione in aperto per valutare la sicurezza di GSK1605786A in soggetti affetti da mor... | 2013-11-14 | due-trials |
| Reported results | 2010-022510-11 | A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevat... | 2012-03-07 | due-trials |
| Reported results | 2010-022538-10 | An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (Engerix-B™ Kinder) vaccine challenge in children ag... | 2011-09-28 | due-trials |
| Reported results | 2010-022742-25 | A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Rec... | 2014-05-21 | due-trials |
| Reported results | 2010-022743-37 | A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Rec... | 2014-02-24 | due-trials |
| Reported results | 2010-022746-24 | A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Re... | 2014-02-20 | due-trials |
| Reported results | 2010-022777-34 | A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905). | 2017-09-13 | due-trials |
| Reported results | 2010-022796-62 | A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD. | 2011-09-02 | due-trials |
| Reported results | 2010-022838-85 | A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma | 2016-12-16 | due-trials |
| Reported results | 2010-022843-39 | Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment | 2014-04-16 | due-trials |
| Reported results | 2010-022857-41 | Effects of a common cold treatment on cognitive function | 2011-04-12 | due-trials |
| Reported results | 2010-023015-33 | MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors and Leukemia | 2018-01-23 | due-trials |
| Reported results | 2010-023066-52 | An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy versus Physicians` Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukaemia (C... | 2017-04-27 | due-trials |
| Reported results | 2010-023091-10 | A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo a... | 2014-11-04 | due-trials |
| Reported results | 2010-023186-21 | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK... | 2013-02-26 | due-trials |
| Reported results | 2010-023348-33 | A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Nove... | 2012-04-20 | due-trials |
| Reported results | 2010-023349-32 | A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Nove... | 2012-05-04 | due-trials |
| Reported results | 2010-023417-54 | A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444... | 2012-07-23 | due-trials |
| Reported results | 2010-023418-29 | HZC113109: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Sal... | 2011-12-13 | due-trials |
| Reported results | 2010-023419-33 | HZC112352: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Sal... | 2012-01-24 | due-trials |
| Reported results | 2010-023442-75 | An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444 | 2012-06-14 | due-trials |
| Reported results | 2010-023444-32 | An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444. | 2012-07-16 | due-trials |
| Reported results | 2010-023837-45 | A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Na�ve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain | 2013-06-12 | due-trials |
| Reported results | 2010-024087-17 | Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients | 2012-02-21 | due-trials |
| Reported results | 2010-024435-16 | A 12-week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arteri... | 2012-08-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-024566-22 | A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subjects w... | bad-data | |
| Reported results | 2011-000114-19 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A... | 2015-12-21 | due-trials |
| Reported results | 2011-000115-11 | A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when administer... | 2011-07-07 | due-trials |
| Reported results Terminated | 2011-000241-21 | A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients | 2013-03-07 | due-trials |
| Reported results | 2011-000242-38 | A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy Studio di 2 anni sull'efficacia e la sicurezza di belimumab per via... | 2013-10-23 | due-trials |
| Reported results | 2011-000243-24 | An open-label, phase 2a study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular agerelated macular degeneration | 2012-04-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-000368-88 | A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standa... | bad-data | |
| Reported results | 2011-000483-94 | A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects... | 2012-09-17 | due-trials |
| Reported results | 2011-000484-28 | A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with fe... | 2012-03-05 | due-trials |
| Reported results Terminated | 2011-000485-35 | A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. Estudio para evaluar la seguridad, tolerabilid... | 2012-03-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-000634-11 | A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in ... | 2013-09-24 | bad-data |
| Reported results | 2011-000757-22 | A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscular... | 2014-11-13 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-000758-41 | A phase III, observer-blind, randomized, multi-country, non-influenza vaccine comparator-controlled study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza ca... | 2014-12-31 | bad-data |
| Trial is partly outside EEC, and reported results | 2011-000876-33 | A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in healthy... | 2012-11-14 | bad-data |
| Reported results | 2011-000943-26 | A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV/Hi... | 2011-07-15 | due-trials |
| Reported results | 2011-001161-41 | A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small c... | 2021-01-07 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-001266-17 | An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy | 2014-03-17 | bad-data |
| Trial is outside EEC, and reported results | 2011-001508-37 | Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine, when administered as primary vaccination integrated into a... | bad-data | |
| Reported results | 2011-001581-18 | Effects of bronchodilatation with salmeterol on the autonomic nervous system | 2012-11-30 | due-trials |
| Reported results | 2011-001608-37 | Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubella ... | 2014-03-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-001643-79 | A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with pers... | 2015-11-03 | bad-data |
| Reported results | 2011-001644-29 | A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma. Klinické ho... | 2015-06-23 | due-trials |
| Reported results | 2011-001645-33 | AC4115408: A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects... | 2012-02-13 | due-trials |
| Reported results | 2011-001900-36 | FFA115285: A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhal... | 2012-09-26 | due-trials |
| Reported results | 2011-002035-26 | A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent Hum... | 2015-10-27 | due-trials |
| Reported results | 2011-002068-26 | A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG) Studio ... | 2015-10-27 | due-trials |
| Trial is outside EEC, and reported results | 2011-002076-16 | Clinical Otitis Media and Pneumonia Study (COMPAS): a phase III , double-blind, randomized, controlled, multicentre study to demonstrate the efficacy of GlaxoSmithKline (GSK) Biologicals’ 10-valent pn... | bad-data | |
| Trial is outside EEC, and reported results | 2011-002077-35 | A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6, 10... | bad-data | |
| Trial is outside EEC, and reported results | 2011-002140-27 | A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumo... | bad-data | |
| Reported results | 2011-002184-17 | A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pat... | 2014-01-02 | due-trials |
| Exempt, with results | 2011-002225-22 | A phase I, randomized, controlled, double-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in health... | not-yet-due | |
| Reported results | 2011-002333-19 | A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months? administration of Ofatumumab in Subjects with Relapsing-Rem... | 2015-06-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-002410-36 | A phase III, open, controlled study to evaluate immunogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine administered intramuscularly to at risk subjects from 1 to less than 18 years and to an ... | bad-data | |
| Reported results | 2011-002451-33 | A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotro... | 2012-12-21 | due-trials |
| Reported results | 2011-002452-13 | A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (... | 2015-11-24 | due-trials |
| Trial is outside EEC, and reported results | 2011-002629-23 | Immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-Hepatitis B vaccine (10 µg) in newborns of Hepa-titis B envelope antigen positive (HBeAg+) and Hepatitis B surface antigen po... | bad-data | |
| Reported results | 2011-002817-12 | A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn's Disease Estudio de tratamien... | 2013-10-17 | due-trials |
| Reported results | 2011-002818-37 | A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients wi... | 2013-01-17 | due-trials |
| Reported results | 2011-002827-17 | A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease. | 2014-04-30 | due-trials |
| Reported results | 2011-002828-41 | A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease. | 2015-03-17 | due-trials |
| Completed, but no date, and reported results Terminated | 2011-002943-92 | A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN™ in Subjects with Pulmonary Arterial Hypertension (PAH) | bad-data | |
| Reported results | 2011-002944-28 | A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of... | 2013-06-12 | due-trials |
| Trial is outside EEC, and reported results | 2011-002946-11 | A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and MMR ... | bad-data | |
| Trial is outside EEC, and reported results | 2011-003167-30 | A randomised, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ IPV vaccine administered as a three-dose primary vaccination course at 2-3-4 months of age in healthy... | bad-data | |
| Reported results | 2011-003255-19 | A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 10 years after the first booster immunization with Tick Borne Encephalitis vaccine in adults who received 1 of 3 ... | 2016-09-30 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-003337-34 | HZA106853: A dose-ranging study of Vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy. | 2014-04-28 | bad-data |
| Trial is partly outside EEC, and reported results | 2011-003338-15 | HZA106855: A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma. | 2019-09-24 | bad-data |
| Trial is outside EEC, and reported results | 2011-003512-23 | A phase II, randomized, observer blind, multicenter study to evaluate the safety and immunogenicity of a single low dose of AS03-adjuvanted, Quebec- or Dresden- manufactured monovalent A/California/7/... | bad-data | |
| Reported results | 2011-003672-36 | A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when ... | 2015-09-18 | due-trials |
| Trial is outside EEC, and reported results | 2011-003710-16 | A phase III, randomized, open, controlled study in healthy Japanese children to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate va... | bad-data | |
| Trial is outside EEC, and reported results | 2011-003711-39 | A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102485... | bad-data | |
| Trial is outside EEC, and reported results | 2011-003731-63 | A phase IV, open, multi-centre study to assess the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese in... | bad-data | |
| Reported results | 2011-003814-18 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst... | 2015-10-01 | due-trials |
| Reported results | 2011-004436-61 | A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin, the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on th... | 2012-11-15 | due-trials |
| Reported results | 2011-004438-32 | A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s di... | 2014-05-01 | due-trials |
| Reported results | 2011-004466-14 | Effects of two doses of a common cold treatment on cognitive function | 2012-10-31 | due-trials |
| Trial is outside EEC, and reported results | 2011-004485-15 | A Phase IIIb, open, randomized study to evaluate non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella vaccine versus co-administration of GSK Biologicals’ Priorix™ and Varilrix™ in heal... | bad-data | |
| Reported results | 2011-004569-33 | A Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’... | 2017-02-06 | due-trials |
| Reported results | 2011-004570-28 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active ... | 2020-03-12 | due-trials |
| Trial is outside EEC, and reported results | 2011-004638-32 | A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when ... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004644-22 | A phase III, randomized, single-blind, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-do... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004650-25 | A phase III, randomized, open, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-dose prima... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004734-33 | A Phase II, non-randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted (pre-) pandemic H5N1 influenza candidate vaccine following a heterologous prime-boost schedule ... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004751-39 | A phase III, randomized, open, active-controlled study to evaluate the safety and immunogenicity of a prime-boost schedule of the H5N1 candidate vaccine adjuvanted with AS03B administered to children ... | bad-data | |
| Reported results | 2011-004800-40 | An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease. Uno studio di estensione in aperto per valutare... | 2016-02-17 | due-trials |
| Trial is outside EEC, and reported results | 2011-004879-36 | Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA Hepatitis B vaccine (10µg) with or without Hepatitis B immunoglobulin (HBIG) in newborns of Hepa... | bad-data | |
| Reported results | 2011-004891-12 | A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & ... | 2015-04-16 | due-trials |
| Trial is outside EEC, and reported results | 2011-004901-25 | An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-D... | bad-data | |
| Reported results | 2011-004905-26 | Immunogenicity and safety study of GSK Biologicals? Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.?s MMR vaccine when both are given on a 2-dose schedule to he... | 2015-08-18 | due-trials |
| Trial is outside EEC, and reported results | 2011-005032-26 | A phase III, open, randomized, controlled, multi-centre study to demonstrate the non-inferiority of the meningococcal serogroup C and the Haemophilus influenzae type b immune response of GlaxoSmithKli... | bad-data | |
| Reported results | 2011-005178-43 | A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL) | 2015-11-30 | due-trials |
| Reported results Terminated | 2011-005216-28 | A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 m... | 2012-08-22 | due-trials |
| Reported results | 2011-005244-95 | A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma | 2013-02-05 | due-trials |
| Reported results | 2011-005553-31 | A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler c... | 2016-12-16 | due-trials |
| Trial is outside EEC, and reported results | 2011-005604-15 | A phase III, randomised, controlled, single-blind study to evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered according to a 2-dose... | bad-data | |
| Reported results | 2011-005667-25 | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | 2022-11-18 | due-trials |
| Reported results | 2011-005672-42 | A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Er... | 2019-01-28 | due-trials |
| Reported results | 2011-005743-27 | A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ 11-valent and 12-valent pneumococcal polysaccharide and ... | 2014-01-22 | due-trials |
| Trial is outside EEC, and reported results | 2011-005860-31 | Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age | bad-data | |
| Trial is outside EEC, and reported results | 2011-005868-25 | A randomised, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course at 2-3-4 or 3-4-5 months... | bad-data | |
| Trial is outside EEC, and reported results | 2011-005881-38 | A phase II, randomized, double-blind study of Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), one lot using new measles and rubella working seeds and one lot using old working seeds,... | bad-data | |
| Trial is outside EEC, and reported results | 2011-005882-19 | Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Priorix... | bad-data | |
| Reported results | 2011-005913-35 | A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in... | 2013-06-11 | due-trials |
| Reported results | 2011-005914-12 | A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in... | 2013-03-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-006013-34 | A phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine when administered to children ... | 2015-06-29 | bad-data |
| Reported results | 2011-006087-49 | A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subject... | 2019-02-28 | due-trials |
| Reported results | 2011-006088-23 | A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectabl... | 2019-04-25 | due-trials |
| Reported results | 2011-006161-18 | A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc.’s ... | 2015-12-22 | due-trials |
| Reported results | 2011-006215-56 | BEL114424: A Phase 2 Pilot, Multicentered, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab plus Standard of Care versus Placebo pl... | 2016-02-08 | due-trials |
| Reported results | 2012-000126-22 | A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM. | 2014-01-07 | due-trials |
| Reported results | 2012-000138-20 | A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B cand... | 2017-02-01 | due-trials |
| Trial is outside EEC, and reported results | 2012-000162-38 | A phase III open-label study to assess the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ Infanrix ... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000254-64 | A phase III, open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10- valent pneumococcal conjugate vaccine administered to children with sickle cell di... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000282-20 | A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of meningococcal vaccine GSK134612 given intramuscularly versu... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000283-23 | A phase III, open, randomized, controlled primary vaccination study to demonstrate the non-inferiority of meningococcal vaccine GSK134612 given intramuscularly versus Mencevax™ ACWY given subcutaneous... | bad-data | |
| Reported results | 2012-000384-24 | A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects with Chronic Obstructive Pulmonary Disease | 2012-10-22 | due-trials |
| Reported results | 2012-000385-38 | BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy | 2016-09-14 | due-trials |
| Reported results | 2012-000523-40 | A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2... | 2014-07-16 | due-trials |
| Reported results | 2012-000524-18 | A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium bromide/vilanterol compared with fluticasone propionate/salmeterol over ... | 2013-10-07 | due-trials |
| Reported results | 2012-000525-45 | DB2114930: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol ov... | 2013-10-25 | due-trials |
| Trial is outside EEC, and reported results | 2012-000741-12 | A Randomized, Double blind, Placebo controlled, Two-Way Crossover 7-day study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25μg in Chi... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000753-31 | A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to invstigate the safety, tolerability,pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 1... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000754-55 | A randomized, double-blind, repeat dose, two period crossover study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of inhaled fluticasone furoate/vilanterol 100/25 mcg... | bad-data | |
| Completed, but no date, and reported results | 2012-000789-39 | A Phase III, open, non-randomized, multi-centre, single dose study to assess immunogenicity and safety of Fluarix/Influsplit SSW 2012/2013 injected intramuscularly in adults (18 to 60 years) and in el... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000819-82 | A phase III, multi-centre, open study to assess antibody persistence after completion of the 3-dose primary vaccination course with GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate ... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000826-23 | A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102485... | bad-data | |
| Reported results | 2012-000927-42 | A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily... | 2014-08-08 | due-trials |
| Trial is outside EEC, and reported results | 2012-001132-60 | Open-label, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years with part... | bad-data | |
| Reported results | 2012-001230-34 | A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity of a revaccination dose of the GlaxoSmithKline Biologicals' quadrivalent seasonal influenza candida... | 2013-06-05 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-001251-40 | A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refra... | 2014-01-18 | bad-data |
| Listed as ongoing, but also has a completion date | 2012-001266-15 | COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio... | 2023-07-31 | bad-data |
| Trial is outside EEC, and reported results | 2012-001305-25 | A phase II, observer-blinded, multi-center, controlled study to assess the safety and immunogenicity of one dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus toxoid conju... | bad-data | |
| Reported results Terminated | 2012-001344-22 | A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and rea... | 2016-09-13 | due-trials |
| Trial is outside EEC, and reported results | 2012-001481-16 | A phase I, double-blind, randomised, placebo-controlled study to assess the reactogenicity and safety of two doses of GlaxoSmithKline Biologicals’ (GSK) oral live attenuated liquid human rotavirus (HR... | bad-data | |
| Reported results | 2012-001497-29 | MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma | 2013-12-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-001499-12 | Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advan... | 2020-12-04 | bad-data |
| Reported results | 2012-001642-17 | An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | 2015-11-18 | due-trials |
| Reported results | 2012-001643-51 | MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial. | 2017-05-31 | due-trials |
| Reported results | 2012-001644-21 | MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials. | 2015-03-16 | due-trials |
| Reported results | 2012-001645-41 | An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. | 2014-04-04 | due-trials |
| Reported results | 2012-001646-18 | A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | 2015-03-30 | due-trials |
| Trial is outside EEC, and reported results | 2012-001683-29 | A Phase 2/3, randomized, controlled, observer-blind, multi-center trial to evaluate the safety and immunogenicity of a two-dose primary vaccination series of monovalent A/Indonesia/5/2005 (H5N1) vacci... | bad-data | |
| Completed, but no date, and reported results Terminated | 2012-001820-36 | A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine GSK 692342 when administered to adu... | bad-data | |
| Reported results | 2012-001871-35 | AC4116136: A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticason... | 2013-08-16 | due-trials |
| Trial is outside EEC, and reported results | 2012-001875-35 | A phase III, randomized, open study to assess the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HR... | bad-data | |
| Reported results | 2012-001876-13 | A Phase III, open, randomized, controlled, multicenter study to assess the immunogenicity and reactogenicity of GSK Biologicals’ meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccin... | 2014-04-29 | due-trials |
| Reported results | 2012-002047-26 | FDC116115: A prospective study of sexual function in sexually active men treated for BPH | 2016-04-05 | due-trials |
| Reported results | 2012-002156-16 | A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks... | 2014-01-09 | due-trials |
| Reported results | 2012-002236-87 | Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes | 2013-03-01 | due-trials |
| Trial is outside EEC, and reported results | 2012-002401-22 | A Phase III, open, randomized, controlled, multicenter study to assess the safety and immunogenicity of GlaxoSmithKline’s Biologicals’ (GSK Biologicals) Neisseria meningitidis serogroups A, C, W-135, ... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002426-70 | Phase III b, open, randomised, multicenter study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002427-15 | A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as compa... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002428-34 | A phase IV, partially double-blind, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as compa... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002439-26 | An open, multicentre, post-marketing surveillance (PMS) study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib vaccine administered at 3 and 4 months of age and DTP... | bad-data | |
| Reported results | 2012-002541-37 | A Phase II, open label, mono-centric study to evaluate the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 in healthy BCG-primed, HIV-neg... | 2013-05-24 | due-trials |
| Trial is outside EEC, and reported results | 2012-002575-34 | A phase IIIb, open, multi-center study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals’ MenACWY-TT vaccine administered at 6 years post-primary vaccinati... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002587-27 | A phase II, double-blind, multicenter, randomized study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza candidate vaccine GSK2321138A compared with GSK Biologicals... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002718-38 | A phase II, open, controlled, multi-center study to evaluate the long-term antibody persistence at 1 year, 3 years and 5 years after the administration of one dose of GlaxoSmithKline (GSK) Biologicals... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002719-24 | A phase II, open, multi-center study to evaluate the long-term anti-body persistence at 1 year, 3 years and 5 years after the administration of one or two doses of GlaxoSmithKline (GSK) Biologicals’ m... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002722-75 | A phase IIb, open, randomised, controlled primary vaccination study to evaluate the non-inferiority and the persistence of the immune response of GSK Biologicals’ meningococcal serogroup ACWY conjugat... | bad-data | |
| Trial is outside EEC, and reported results | 2012-002727-15 | A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-typeabl... | bad-data | |
| Completed, but no date, and reported results | 2012-002737-11 | A Phase III, randomised, partially-blind, controlled, multi-centric, multi-country study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine co-a... | bad-data | |
| Reported results | 2012-002790-55 | A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected PRAME-pos... | 2016-08-24 | due-trials |
| Reported results | 2012-002797-32 | A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticaso... | 2013-10-15 | due-trials |
| Reported results | 2012-002917-20 | A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis | 2014-03-24 | due-trials |
| Reported results | 2012-002966-11 | A phase II/III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the immunogenicity and safety of GSK Biologicals? herpes zoster HZ/su candidate vaccine when admin... | 2016-05-20 | due-trials |
| Trial is outside EEC, and reported results | 2012-003025-25 | A phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly accor... | bad-data | |
| Reported results Terminated | 2012-003105-10 | Study PTG116878, a Dose-Optimization Study of ezogabine/retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures. | 2013-06-20 | due-trials |
| Reported results | 2012-003106-27 | A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inh... | 2013-07-17 | due-trials |
| Trial is outside EEC, and reported results | 2012-003324-20 | An open-label study to assess the immune persistence in healthy Chinese toddlers primed in infancy with three doses of GSK Biologicals’ DTPa-IPV/Hib vaccine, and to assess the safety and immunogenicit... | bad-data | |
| Reported results | 2012-003349-13 | Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis | 2015-01-28 | due-trials |
| Reported results | 2012-003438-18 | A Phase III, randomised, observer-blind, placebo controlled,multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intra... | 2017-01-06 | due-trials |
| Reported results | 2012-003627-38 | Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis | 2014-09-12 | due-trials |
| Reported results | 2012-003937-41 | Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following... | 2015-12-27 | due-trials |
| Reported results | 2012-003950-10 | An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a challenge dose of Engerix™-B Kinder in adolescents... | 2014-02-21 | due-trials |
| Reported results | 2012-003973-24 | A Multicenter Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily with Tiotropium 18 mcg Once Daily over 24 Weeks in Subjects with Chronic Obstructive Pulmonary D... | 2014-01-24 | due-trials |
| Trial is outside EEC, and reported results | 2012-004039-21 | An open, multicentric, post-marketing surveillance study to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ live attenuated oral Human Rotavirus (HRV) vaccine, Rotarix when admi... | bad-data | |
| Reported results | 2012-004049-34 | A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant ... | 2013-05-30 | due-trials |
| Reported results | 2012-004050-29 | A four-week Phase IIa, randomized, double-blind, placebocontrolled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia assoc... | 2013-05-07 | due-trials |
| Trial is outside EEC, and reported results | 2012-004060-22 | A phase II, open, controlled, multicenter study to evaluate the long-term antibody persistence at 1, 3 and 5 years after the administration of a four dose vaccination series of Hib-MenCY-TT vaccine co... | bad-data | |
| Trial is outside EEC, and reported results | 2012-004137-16 | A phase III, randomized, open-label, multicentre study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ combined DTPa-IPV/Hib vaccine administered as a three-dos... | bad-data | |
| Trial is outside EEC, and reported results | 2012-004380-44 | A Phase II, open-label, randomised controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine (M72/AS01E) when administered intr... | bad-data | |
| Reported results | 2012-004385-17 | A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Stand... | 2016-09-05 | due-trials |
| Reported results | 2012-004456-11 | A phase III, randomised, open-label, multicentre, clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su vaccine when administered intramuscularly according to a 0,2-month sc... | 2015-04-08 | due-trials |
| Reported results Terminated | 2012-004494-23 | Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients | 2014-07-28 | due-trials |
| Trial is outside EEC, and reported results | 2012-004513-14 | An open-label study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV vaccine (Poliorix) administered as a booster dose at 18 months of age in healthy Chinese t... | bad-data | |
| Reported results | 2012-004577-12 | Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tramet... | 2017-01-19 | due-trials |
| Reported results | 2012-004801-28 | Multi-centre, randomized, double-blind, parallel-group study evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder once daily compared with Vilanterol (VI) Inhalation Powd... | 2018-03-26 | due-trials |
| Reported results | 2012-004891-20 | A randomised, double-blind (sponsor-unblind), placebo controlled, cross-over study to investigate the efficacy, effect on cough reflex sensitivity, safety, tolerability and pharmacokinetics of inhaled... | 2014-10-02 | due-trials |
| Reported results | 2012-005007-41 | A Randomised, Double Blind, Double Dummy, Parallel Group Study Comparing UMEC/VI (A Fixed Combination Of Umeclidinium and Vilanterol) With Tiotropium In COPD Subjects Who Continue To Have Symptoms on ... | 2015-07-22 | due-trials |
| Reported results | 2012-005059-18 | A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals' HZ/su candidate vaccine when administered intramuscu... | 2017-04-13 | due-trials |
| Trial is outside EEC, and reported results | 2012-005200-18 | A phase III, double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated liquid human rotav... | bad-data | |
| Reported results | 2012-005314-19 | A phase III, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23 in ... | 2016-06-17 | due-trials |
| Trial is outside EEC, and reported results | 2012-005639-10 | A phase IIIb, open, multi-center study to evaluate the long-term anti-body persistence at 6, 7, 8, 9 and 10 years after the administration of one dose of GlaxoSmithKline (GSK) Biologicals’ meningococc... | bad-data | |
| Trial is outside EEC, and reported results | 2012-005641-21 | A phase III, open, controlled study to assess the persistence of antibodies after one dose of GlaxoSmithKline Biologicals’ meningococcal serogroup ACWY conjugate vaccine (MenACWY-TT) given intramuscul... | bad-data | |
| Reported results | 2012-005671-14 | A phase III, randomised, open-label, multicentre clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su candidate vaccine when administered subcutaneously as compared to intr... | 2014-11-11 | due-trials |
| Trial is outside EEC, and reported results | 2012-005695-34 | A Phase II randomized, open, controlled study of the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate Plasmodium falciparum malaria vaccine RTS,S/AS01E, when incorporated into an Ex... | bad-data | |
| Trial is outside EEC, and reported results | 2012-005716-26 | A phase III, double blind (observer-blind), randomized, controlled multi-center study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease ca... | bad-data | |
| Trial is outside EEC, and reported results | 2012-005718-20 | A phase 2, open, randomized, controlled, multi-center study to evaluate the safety and immunogenicity of 7 infant immunization schedules of the RTS,S/AS01E candidate vaccine against P. falciparum. | bad-data | |
| Reported results | 2013-000372-15 | A phase III, randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’... | 2015-03-20 | due-trials |
| Completed, but no date, and reported results | 2013-000373-76 | A phase III, randomized, double blind multicenter study, to evaluate consistency, immunogenicity, safety and reactogenicity of 3 lots of GSK Biologicals’ herpes zoster HZ/su candidate vaccine when adm... | bad-data | |
| Exempt, with results | 2013-000445-39 | A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malign... | 2020-04-30 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2013-000572-15 | Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity: ex vivo T cell biology investigation relating to lapatinib induced liver adverse events using PBMCs from patients se... | 2014-04-30 | bad-data |
| Reported results | 2013-000642-20 | A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenou... | 2017-01-25 | due-trials |
| Reported results | 2013-000657-50 | A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) S... | 2015-12-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000684-85 | A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients ... | 2021-11-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-000685-11 | A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer | 2021-12-26 | bad-data |
| Exempt | 2013-000686-37 | A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas | 2018-06-06 | not-yet-due |
| Completed, but no date, and reported results | 2013-000855-42 | A Phase III, open-label, non-randomised, multi-centre, single dose study to assess immunogenicity and safety of Fluarix / Influsplit SSW 2013/2014 injected intramuscularly in adults (18 to 60 years of... | bad-data | |
| Reported results | 2013-000918-37 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-ri... | 2016-04-28 | due-trials |
| Reported results | 2013-000992-33 | A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel versus Controls in Ankle Sprain | 2015-03-22 | due-trials |
| Completed, but no date, and reported results | 2013-001094-25 | A Phase III, open-label, non-randomised, multi-centre, single dose study to assess the immunogenicity and safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Influspli... | bad-data | |
| Reported results | 2013-001370-20 | OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris | 2016-12-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-001371-20 | Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag | 2022-02-23 | bad-data |
| Completed, but no date, and reported results | 2013-001699-39 | A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advance... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2013-001705-87 | A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Tra... | 2021-12-10 | bad-data |
| Reported results | 2013-001827-38 | Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic subje... | 2015-05-04 | due-trials |
| Completed, but no date, and reported results | 2013-001918-15 | A phase IV, open-label, single-centre study to assess the long-term persistence of hepatitis A antibodies in healthy adults, primed 21 to 25 years earlier with GSK Biologicals’ hepatitis A vaccine Hav... | bad-data | |
| Reported results | 2013-002238-19 | A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study... | 2014-04-01 | due-trials |
| Reported results | 2013-002239-44 | A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study... | 2014-04-21 | due-trials |
| Reported results | 2013-002418-11 | A study to evaluate the effect of a 67% Sodium Bicarbonate containing toothpaste on Chlorhexidine Digluconate tooth staining | 2013-11-20 | due-trials |
| Reported results | 2013-002451-15 | A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Me... | 2016-11-03 | due-trials |
| Trial is outside EEC, and reported results | 2013-002537-37 | A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biologicals' meningococcal conjugate vaccine, MenACWY-TT (GSK 134612) in healthy inf... | bad-data | |
| Trial is outside EEC, and reported results | 2013-002538-18 | A phase III, single-group, open-label, multicentre study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-... | bad-data | |
| Reported results | 2013-002681-39 | A 24-week, Phase 2B, randomized, active-controlled, parallel group, multi-center study to evaluate the safety and efficacy of GSK1278863 in subjects with anemia associated with chronic kidney disease ... | 2015-06-03 | due-trials |
| Reported results | 2013-002682-19 | A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and ev... | 2015-02-06 | due-trials |
| Trial is outside EEC, and reported results | 2013-002804-15 | A phase IV, open-label, multicentre, non-comparative study to assess reactogenicity and safety of co-administration of GlaxoSmithKline (GSK) Biologicals’ inactivated poliomyelitis vaccine PoliorixTM a... | bad-data | |
| Reported results | 2013-002821-41 | Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine EngerixTM-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of Infa... | 2014-09-23 | due-trials |
| Reported results | 2013-002940-94 | A randomised, double-blind, placebo-controlled, 3 way, incomplete block cross over study in subjects with allergic rhinitis to assess the effect of once daily single and repeat doses of intranasal Flu... | 2014-02-20 | due-trials |
| Reported results | 2013-003062-13 | A Phase II, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational vaccine GSK2838504A, when a... | 2017-04-19 | due-trials |
| Reported results | 2013-003073-10 | A Phase III, 24 week, randomized, double blind, double dummy, parallel group study (with an extension to 52 weeks in a subset of subjects) comparing the efficacy, safety and tolerability of the fixed ... | 2016-04-07 | due-trials |
| Reported results | 2013-003075-35 | A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual com... | 2017-07-17 | due-trials |
| Reported results | 2013-003111-22 | A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophil... | 2015-12-22 | due-trials |
| Trial is outside EEC, and reported results | 2013-003155-38 | A Phase III, double-blind, randomised, controlled, multi-country, multi-centre study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine candidate, GSK2282512A... | bad-data | |
| Reported results | 2013-003296-34 | A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Otelixiz... | 2018-09-27 | due-trials |
| Trial is outside EEC, and reported results | 2013-003427-10 | A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to Indi... | bad-data | |
| Trial is outside EEC, and reported results | 2013-003428-34 | A phase IV, non-randomised, open-label, multicentre study with two parallel groups to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine admin... | bad-data | |
| Reported results | 2013-003429-28 | A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscularl... | 2017-04-19 | due-trials |
| Reported results | 2013-003452-21 | BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain | 2018-02-14 | due-trials |
| Trial is outside EEC, and reported results | 2013-003459-39 | A phase IIIb, open, randomized, controlled, multicenter study to assess the co-administration of Rotarix (GlaxoSmithKline Biologicals’) with Hib-MenCY-TT (GlaxoSmithKline Biologicals’ Meningococcal Gr... | bad-data | |
| Trial is outside EEC, and reported results | 2013-003479-36 | A phase III, controlled, partially-blind study to assess the reactogenicity, safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae... | bad-data | |
| Reported results | 2013-003510-41 | A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symptom... | 2016-08-29 | due-trials |
| Reported results | 2013-003535-30 | A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the second y... | 2016-10-25 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-003595-12 | A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors Etude de phase II du pazopanib (GW786034, N° NSC 737754) chez des enfant... | 2019-11-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-003596-35 | An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subject... | 2020-12-29 | bad-data |
| Trial is outside EEC, and reported results | 2013-003768-30 | A phase IV, single-blind, randomized, multicenter study to assess the immunogenicity and safety of GSK Biologicals’ dTpa vaccine (Boostrix™) using a new syringe presentation in healthy adolescents age... | bad-data | |
| Trial is outside EEC, and reported results | 2013-003859-37 | A phase III, single-group, open-label study to assess the safety and reactogenicity of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine Boostrix ... | bad-data | |
| Trial is outside EEC, and reported results | 2013-004158-81 | A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate a... | bad-data | |
| Trial is outside EEC, and reported results | 2013-004194-27 | A Phase III, randomized, multicenter study, double-blind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenzae type b (Hib) conjugate vaccine and singl... | bad-data | |
| Reported results | 2013-004297-98 | Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level. | 2017-01-16 | due-trials |
| Reported results | 2013-004298-28 | Study 117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients. Estudio 117106: Mepolizumab frente a placebo como tratamiento complementario en pacientes con EP... | 2017-01-17 | due-trials |
| Trial is outside EEC, and reported results | 2013-004304-19 | A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary vacc... | bad-data | |
| Reported results | 2013-004548-44 | A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily ... | 2015-07-08 | due-trials |
| Completed, but no date, and reported results | 2013-004586-13 | A phase IV, open-label, multi-centre study to assess the long-term persistence of hepatitis A and B antibodies in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined h... | bad-data | |
| Completed, but no date, and reported results Terminated | 2013-004778-84 | A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals? MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10 to... | bad-data | |
| Trial is outside EEC, and reported results | 2013-005577-43 | A phase III, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of... | bad-data | |
| Reported results Terminated | 2014-000060-17 | A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to a 2... | 2014-07-29 | due-trials |
| Trial is outside EEC, and reported results | 2014-000101-12 | A phase III, multi-centre, double-blind, randomised study to assess the non-inferiority of a commercial lot of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine... | bad-data | |
| Reported results | 2014-000256-28 | A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the ... | 2017-10-19 | due-trials |
| Completed, but no date, and reported results | 2014-000313-31 | A double-blind (sponsor unblind), placebo controlled, randomised, parallel group study to evaluate the safety, tolerability and pharmacokinetics of multiple doses of GSK2269557 administered as a dry p... | bad-data | |
| Trial is partly outside EEC, and reported results | 2014-000314-54 | Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial | 2017-10-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-000499-24 | Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Studies | 2019-09-02 | bad-data |
| Reported results | 2014-000529-19 | A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD | 2015-03-05 | due-trials |
| Reported results | 2014-000551-81 | A 6-month, open label, randomised, efficacy study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via the Dry Powder Inhaler Ellipta™ co... | 2017-07-20 | due-trials |
| Reported results | 2014-000611-14 | A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulm... | 2015-03-24 | due-trials |
| Reported results Terminated | 2014-000643-33 | A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery. | 2017-08-09 | due-trials |
| Trial is outside EEC, and reported results | 2014-000750-11 | Study to compare immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infan... | bad-data | |
| Reported results | 2014-000883-16 | A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component | 2015-08-18 | due-trials |
| Reported results | 2014-000884-42 | A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmo... | 2015-06-15 | due-trials |
| Reported results | 2014-000885-23 | A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Di... | 2015-06-02 | due-trials |
| Reported results | 2014-000955-10 | A Phase III, double-blind, randomized, multicenter study to assess safety and immunogenicity of GlaxoSmithKline Biologicals? Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) manufactured with... | 2015-04-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-001117-41 | A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of Infanrix hexa? administered as primary vaccination in healthy infants born to mothers given Boostr... | 2018-09-24 | bad-data |
| Reported results | 2014-001118-24 | A Phase III, placebo-controlled, observer-blind, randomised, multi-centre study to describe the immunogenicity and safety of GSK Biologicals’ Quadrivalent Split Virion Influenza Vaccine 2014/2015 Infl... | 2015-05-04 | due-trials |
| Reported results | 2014-001119-38 | A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. Estudio multicéntr... | 2017-10-24 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-001120-30 | A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa? in healthy infants born to mothers vaccinated with Boostrix? duri... | 2019-07-11 | bad-data |
| Exempt, with results | 2014-001197-34 | A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in subjects with End Stage Renal Disease undergoing peritoneal dialysis. | 2017-05-10 | not-yet-due |
| Reported results | 2014-001220-30 | An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in C... | 2020-05-06 | due-trials |
| Reported results | 2014-001232-11 | Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic... | 2019-08-08 | due-trials |
| Reported results | 2014-001821-34 | Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study | 2017-07-24 | due-trials |
| Reported results | 2014-001824-32 | A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patie... | 2018-03-12 | due-trials |
| Reported results Terminated | 2014-001825-33 | Study 110933: Albiglutide versus Placebo in insulin-treated Subjects with new-onset type 1 diabetes mellitus | 2017-10-18 | due-trials |
| Reported results | 2014-001826-13 | Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor | 2017-08-25 | due-trials |
| Reported results | 2014-001969-27 | Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus | 2015-06-10 | due-trials |
| Reported results | 2014-001972-70 | A randomised, double-blind (sponsor unblinded), placebocontrolled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in a... | 2016-05-25 | due-trials |
| Reported results | 2014-002253-19 | A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250... | 2016-11-25 | due-trials |
| Reported results | 2014-002513-27 | A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic as... | 2016-06-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-002666-76 | An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma | 2018-01-31 | bad-data |
| Reported results | 2014-002688-14 | A Phase II, randomised, observer-blind, controlled, multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of different formulations of GlaxoSmithKl... | 2016-06-21 | due-trials |
| Reported results | 2014-002992-27 | 201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD). | 2016-06-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003162-25 | Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Su... | 2023-02-16 | bad-data |
| Reported results | 2014-003326-41 | Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor | 2017-07-24 | due-trials |
| Reported results | 2014-003453-34 | A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoi... | 2017-12-29 | due-trials |
| Reported results | 2014-003808-77 | A multi-centre, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, and tolerability of repeat doses of inhaled GSK2269557 in adults with persistent, unc... | 2016-09-28 | due-trials |
| Trial is outside EEC, and reported results | 2014-004714-28 | A Phase 2, randomised, observer-blind, controlled, multi country study to assess the safety and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational recombinant chimpanzee... | bad-data | |
| Exempt, with results | 2014-004982-25 | A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other c... | 2019-07-29 | not-yet-due |
| Reported results | 2014-005149-40 | An open label non randomized access study of Trametinib for patients with advanced unresectable (stage IIIc) or distant metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma | 2017-03-01 | due-trials |
| Trial is outside EEC, and reported results | 2014-005282-78 | A phase IV, randomised, open-label, controlled study to assess the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids™ when co-admi... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-000382-31 | A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophyl... | 2023-03-15 | bad-data |
| Reported results | 2015-000400-26 | A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subje... | 2020-06-23 | due-trials |
| Reported results | 2015-000841-22 | A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma | 2015-12-21 | due-trials |
| Other | 2015-000952-11 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ... | not-yet-due | |
| Reported results | 2015-000965-30 | A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intram... | 2019-03-15 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-001152-29 | 201956: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study 201956: Programma di accesso a lungo termine per soggetti con asm... | 2022-08-31 | bad-data |
| Trial is outside EEC, and reported results | 2015-001258-13 | A phase III, observer-blind, multi-centre, multi-country, randomized study to evaluate the immunogenicity and safety of thimerosal-free (TF) Fluarix™ (GSK Biologicals) compared with Fluzone® (Sanofi P... | bad-data | |
| Reported results | 2015-001409-15 | Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD. | 2016-07-06 | due-trials |
| Trial is outside EEC, and reported results | 2015-001449-93 | A phase II, observer-blind follow-up study with two groups to assess the reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine (GSK1024850A),... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001484-39 | A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human r... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001485-26 | A phase III, double-blind, randomised, placebo-controlled, multi-center study to assess the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rot... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001505-14 | A phase III, randomized, controlled, single-blind study to evaluate the non-inferiority of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate vaccine compared to the 7-valent pneumococcal c... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001506-34 | A phase III, controlled, single-blind study to assess the reactogenicity, safety and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001507-31 | A phase IIIb, open-label, multicentre study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-acellular pertussis (DTPa)- Haemophilus influenzae... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001508-71 | An open, phase IIIb, randomized, multicentric clinical trial to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ DTPa-IPV vaccine versus co-administration of... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001509-15 | A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/0.5 mL dose] administe... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001510-10 | A phase III, single group, open study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine in Mexico when co-administe... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001511-12 | A phase III, single group, open study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine in Taiwan when co-administe... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001512-35 | An open, multicentric, post-marketing surveillance (PMS) study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib vaccine administered at 3, 4, 5 and 18 months of age... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001513-27 | An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001514-97 | A Phase 3, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion, se... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001515-12 | A phase III, open, randomized, multicentre, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Bio’s combined hepatitis A / hepatitis B vaccine (at leas... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001516-35 | An open study to evaluate the immunogenicity, safety, and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 72... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001517-27 | An open multicentre, multicountry study to evaluate long-term anti-body persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinat... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001530-25 | A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/ 0.5 mL dose] administ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001531-20 | A phase III, single-blinded, randomized, multicentric study to compare the immunogenicity of GlaxoSmithKline Biologicals' thiomersal-free 2-dose Engerix™-B (20 mcg) and 3-dose preservative-free Engeri... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001538-25 | A Phase I/IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine in infants living in a malaria-endemic region | bad-data | |
| Trial is outside EEC, and reported results | 2015-001539-19 | A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine, when incorporated into an Expanded Program on Imm... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001540-10 | A phase III, double-blind, randomised, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001541-92 | A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001542-29 | A phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. | bad-data | |
| Trial is outside EEC, and reported results | 2015-001543-36 | A phase III, double-blind, randomised, placebo-controlled, multi-centre study in Japan to assess the efficacy, safety, reactogenicity and immunogenicity of the lyophilised formulation of GlaxoSmithKli... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001544-11 | A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human r... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001545-81 | A Phase IV, double-blind, randomised, placebo-controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoS-mithKline (GSK) Biologicals’ oral live attenuated HRV vaccine in healthy ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001546-28 | Open, multi-centric, post-marketing surveillance (PMS) to evaluate the reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001547-37 | A Phase I, double-blind, randomised, placebo controlled study to evaluate the reactogenicity and safety of a single oral dose of GlaxoSmithKline (GSK) Biologicals’ live attenuated liquid human rotavir... | bad-data | |
| Reported results | 2015-001758-14 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis | 2018-03-21 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-001778-17 | A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicit... | 2023-06-28 | bad-data |
| Reported results | 2015-002330-42 | Assessment of cognitive function and mobility in individuals with pain | 2017-01-13 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-002361-32 | A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asth... | 2019-07-24 | bad-data |
| Reported results | 2015-002812-33 | A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function in ... | 2018-03-06 | due-trials |
| Reported results | 2015-003089-96 | A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis. | 2017-11-29 | due-trials |
| Completed, but no date, and reported results | 2015-003094-15 | A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subject... | bad-data | |
| Reported results | 2015-003391-74 | Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine, Engerix™-B Kinder (SKF103860) challenge dose, in adolescents vaccinated with four doses of Inf... | 2017-07-05 | due-trials |
| Trial is outside EEC, and reported results | 2015-003405-42 | A phase III, open-label, single-group, multi-centre study to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ combined reduced antigen content diphtheria, tetanus and acellular... | bad-data | |
| Trial is partly outside EEC, and reported results | 2015-003458-42 | A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2005... | bad-data | |
| Reported results | 2015-003696-30 | A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks... | 2018-06-22 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-003697-32 | A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab ... | 2017-05-31 | bad-data |
| Completed, but no date, and reported results | 2015-004099-31 | Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B. | bad-data | |
| Reported results | 2015-004386-91 | A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs | 2017-10-30 | due-trials |
| Reported results | 2015-004400-30 | A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 120 p... | 2018-10-08 | due-trials |
| Reported results | 2015-004790-32 | A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemodia... | 2017-01-21 | due-trials |
| Trial is outside EEC, and reported results | 2015-004864-12 | A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmet... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004865-10 | A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Asthma, Who Have Ei... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004866-27 | A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and sal... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004867-35 | A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Tre... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004868-11 | A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily compared... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004869-88 | A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell tran... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004870-14 | A multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with or... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004871-59 | A randomised, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004872-31 | The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age | bad-data | |
| Trial is outside EEC, and reported results | 2015-004873-34 | A Comparison of Fluticasone Furoate Nasal Spray (FFNS) versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis | bad-data | |
| Trial is outside EEC, and reported results | 2015-004874-13 | An open label study to determine the pharmacokinetic profiles of amoxicillin and clavulanate in adolescent patients weighing at least 40kg and no more than 16 years of age receiving AUGMENTIN™XR (amox... | bad-data | |
| Reported results | 2015-004876-31 | An open-label, single arm study to investigate the safety, pharmacokinetics and pharmacodynamics of repeat doses of inhaled nemiralisib in patients with APDS/PASLI | 2020-06-04 | due-trials |
| Trial is outside EEC, and reported results | 2015-004878-15 | A multi-center, uncontrolled, open-label, evaluation of lamotrigine monotherapy in adult subjects with newly diagnosed epilepsy or recurrent epilepsy (currently untreated). | bad-data | |
| Trial is outside EEC, and reported results | 2015-004880-35 | A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents | bad-data | |
| Trial is outside EEC, and reported results | 2015-004881-27 | Clinical assessment of GW815SF Salmeterol/fluticasone propionate (HFA MDI) in pediatric patients with bronchial asthma -A long term (24-week) study- | bad-data | |
| Trial is outside EEC, and reported results | 2015-004882-10 | A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI | bad-data | |
| Trial is outside EEC, and reported results | 2015-004883-12 | A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Tre... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004884-35 | A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88 mcg administered twice-daily for 28 days delive... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004885-27 | A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis | bad-data | |
| Trial is outside EEC, and reported results | 2015-004886-98 | A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-In... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004887-13 | A Randomized, Double-Blind, Parallel Group study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, both twice daily, in a Pediatric Population during the Fall Viral Season. | bad-data | |
| Trial is outside EEC, and reported results | 2015-004888-37 | A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004889-28 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent su... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004890-34 | Phase III study of adefovir dipivoxil tablets in patients with compensated chronic hepatitis B (comparative study against lamivudine). | bad-data | |
| Trial is outside EEC, and reported results | 2015-004891-31 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescent... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004892-61 | A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Tre... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004893-14 | A Randomised, Multi-centre, Double-blind, Double-dummy, two way cross-over, twelve weeks noninferiority study to evaluate the efficacy, safety and tolerability of combination dry powder Fluticasone Pr... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004898-32 | Pediatric Asthma Clinical Effectiveness study (PEACE). A Randomized, Double-Blind, Double Dummy, Parallel Group comparative clinical study of Salmeterol/Fluticasone propionate Inhalation Powder (50/10... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004899-30 | Multi-center, Randomised, Double-blind, Parallel, Placebo Controlled Study Of 0.05% Clobetasone Butyrate Cream in Subjects with Eczema to evaluate the Efficacy and Safety. | bad-data | |
| Trial is outside EEC, and reported results | 2015-004900-44 | A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl peroxide/Clindamycin gel and Tazarotene cream when used in combination in the Treatmen... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004901-18 | Clinical Evaluation of lamotrigine in Epilepsy | bad-data | |
| Trial is outside EEC, and reported results | 2015-004902-41 | Clinical Evaluation of 506U78 in Japanese Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | bad-data | |
| Trial is outside EEC, and reported results | 2015-004903-22 | A randomized, double-blind, multicenter, superiority Phase III study to assess the safety and efficacy of Topical Retapamulin Ointment 1%, applied twice daily versus Placebo Ointment in Adults and Chi... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004905-17 | A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder | bad-data | |
| Trial is outside EEC, and reported results | 2015-004907-22 | A multicenter, open-label study to assess the efficacy and safety of potassium clavulanate/amoxicillin (CVA/AMPC 1:14 combination) in the treatment of [Japanese] children with acute bacterial rhinosin... | bad-data | |
| Trial is outside EEC, and reported results | 2015-004909-16 | A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% clindamycin as clindamycin phosphate and 5% benzoyl per... | bad-data | |
| Reported results | 2015-005120-26 | A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital G... | 2016-07-27 | due-trials |
| Reported results | 2015-005212-14 | A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (... | 2017-05-23 | due-trials |
| Reported results | 2015-005645-31 | A randomised, double-blind (sponsor open) placebo-controlled, parallel group, 8-week treatment study to investigate the safety, pharmacodynamics, and effect of the TLR7 agonist, GSK2245035, on the all... | 2018-05-04 | due-trials |
| Reported results | 2015-005742-58 | A phase II, randomised, observer-blind, controlled, study to assess the reactogenicity and safety of a single intramuscular dose of GlaxoSmithKline (GSK) Biologicals’ investigational respiratory syncy... | 2016-06-28 | due-trials |
| Reported results Terminated | 2015-005800-27 | A randomised, multi-center, double blind (sponsor open), placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3117391 in subjects with mod... | 2017-11-18 | due-trials |
| Exempt, with results | 2016-000117-76 | A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) inv... | 2021-03-31 | not-yet-due |
| Reported results | 2016-000276-23 | A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis | 2019-01-03 | due-trials |
| Trial is outside EEC, and reported results | 2016-000290-20 | Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or witho... | bad-data | |
| Reported results | 2016-000507-86 | A 52-week open-label (sponsor-blind), randomized, active controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoietin ... | 2020-09-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000541-31 | A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate... | 2020-11-09 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-000542-65 | A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to eva... | 2021-04-19 | bad-data |
| Reported results | 2016-000585-36 | A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) | 2017-04-27 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-000598-19 | A phase IIIA, randomised, observer-blind, multi-centre study to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of GlaxoSmithKline (G... | 2018-11-26 | bad-data |
| Trial is outside EEC, and reported results | 2016-000644-34 | A phase III, open, randomised, multicentre study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ combined reduced antigen content diphtheria-tetanus toxoids and acellular... | bad-data | |
| Trial is outside EEC, and reported results | 2016-000645-31 | A phase II, partially double-blind, randomised, controlled, single-centre study to assess the immunogenicity and reactogenicity of three different formulations of GSK Biologicals’ DTPw-HBV-IPV/Hib can... | bad-data | |
| Other | 2016-000744-34 | A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes ... | not-yet-due | |
| Reported results | 2016-000912-13 | A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subj... | 2018-10-22 | due-trials |
| Reported results | 2016-001135-12 | A Phase II, randomised, observer-blind, controlled, multi-country study to rank different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), based on immunogenicity, reactogen... | 2018-02-05 | due-trials |
| Completed, but no date, and reported results Terminated | 2016-001244-19 | A Phase II, multicenter, randomized, double-blind (sponsor-unblind), placebo- controlled, parallel group trial to evaluate the efficacy and safety of sirukumab in subjects with severe, poorly controll... | bad-data | |
| Reported results | 2016-001304-37 | A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combin... | 2019-02-22 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-001831-10 | An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study... | 2017-08-08 | bad-data |
| Trial is partly outside EEC, and reported results | 2016-001832-36 | An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study ... | 2017-11-30 | bad-data |
| Reported results | 2016-001833-29 | A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and effi... | 2019-06-17 | due-trials |
| Reported results | 2016-002230-69 | A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response to ... | 2018-10-11 | due-trials |
| Exempt, with results Terminated | 2016-002294-35 | A phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult ... | 2017-12-14 | not-yet-due |
| Reported results | 2016-002405-19 | An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug pro... | 2017-08-11 | due-trials |
| Reported results | 2016-002416-41 | A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary b... | 2020-04-16 | due-trials |
| Reported results | 2016-002512-40 | A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospitali... | 2017-05-24 | due-trials |
| Reported results | 2016-002513-22 | A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidimium, and Salmeterol in subjects with chronic obstructive pu... | 2018-06-18 | due-trials |
| Reported results | 2016-002551-22 | Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg once daily ... | 2021-06-04 | due-trials |
| Exempt, with results | 2016-002671-10 | A two-part trial to evaluate the safety, tolerability, clinical effect and systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque psoriasis | 2017-05-05 | not-yet-due |
| Exempt, with results Terminated | 2016-002733-30 | A Phase I/II, randomised, observer-blind, controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational RSV ... | 2017-07-14 | not-yet-due |
| Reported results | 2016-002843-40 | A Phase IIb, 24 week, randomized, double-blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powde... | 2018-05-30 | due-trials |
| Reported results | 2016-003002-14 | An escalating dose, randomized, placebo-controlled incomplete block, 2-period cross-over study to assess the dose response for topical efficacy via airway responsiveness to adenosine-5'-monophosphate ... | 2018-12-20 | due-trials |
| Reported results | 2016-003050-32 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects wit... | 2021-07-07 | due-trials |
| Exempt, with results | 2016-003074-40 | A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ b... | 2021-07-19 | not-yet-due |
| Trial is outside EEC, and reported results | 2016-003186-25 | A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Health... | bad-data | |
| Trial is outside EEC, and reported results | 2016-003210-27 | A phase IIIA, randomized, single-blind, multi-centric study to evaluate the immunogenicity, reactogenicity and safety of three doses of Pediarix, Hiberix and Prevenar 13 when co-administered with two ... | bad-data | |
| Trial is outside EEC | 2016-003268-37 | A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Ad... | bad-data | |
| Reported results | 2016-003417-95 | A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explore ... | 2020-07-07 | due-trials |
| Trial is outside EEC, and reported results | 2016-003479-22 | Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma | bad-data | |
| Reported results | 2016-003675-21 | Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for... | 2018-10-05 | due-trials |
| Trial is partly outside EEC | 2016-003722-16 | A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine when Administered Concomitantly with GSK Meningococcal MenACWY ... | bad-data | |
| Trial is partly outside EEC, and reported results | 2016-004086-87 | A randomized, double-blind, parallel group, multicenter, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation powder compared to once daily flut... | 2022-03-31 | bad-data |
| Reported results | 2016-004255-70 | A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal p... | 2019-12-11 | due-trials |
| Reported results Terminated | 2016-004258-14 | A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-α Monoclonal Antibody (GSK2618960) in the ... | 2017-10-12 | due-trials |
| Trial is outside EEC, and reported results | 2016-004420-29 | A Phase 2, Open-label, Controlled, Multi-Center Extension Study to Evaluate 4-Year Antibody Persistence and Booster Response Fol-lowing MenABCWY Vaccination in Healthy Adolescents and Young Adults who... | bad-data | |
| Trial is outside EEC, and reported results | 2016-005117-44 | A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal group B Vaccine When Administered Concomitantly with Novartis MenACWY Conjugate ... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000093-11 | A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Athe Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococ... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000166-30 | A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GSK Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subject... | bad-data | |
| Trial is partly outside EEC, and reported results | 2017-000184-32 | A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622 | 2019-12-30 | bad-data |
| Reported results | 2017-000212-41 | An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants with Pulmonary Arterial Hypertension | 2019-05-07 | due-trials |
| Trial is outside EEC, and reported results | 2017-000255-50 | A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three dos... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000416-42 | A phase IIIb, double-blind, randomized, controlled, multicentre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 AS04 vaccine administered intramuscularly acc... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000451-14 | An open, single group, multi-centric, post marketing surveillance (PMS) to monitor the reactogenicity and safety of oral live attenuated human rotavirus (HRV) vaccine, Rotarix when administered accord... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000454-18 | A Phase II randomized, observer blind, multicenter study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV) versus ProQuad, according to a one dose schedule,... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000458-20 | A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillo-mavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filipino... | bad-data | |
| Reported results | 2017-000880-34 | A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine GSK3... | 2020-06-12 | due-trials |
| Reported results | 2017-001069-25 | Randomized double blind (sponsor unblind) study evaluating the effect of 14 days of treatment with danirixin (GSK1325756) on neutrophil extracellular traps (NETs) formation in participants with stable... | 2018-10-08 | due-trials |
| Reported results Terminated | 2017-001074-42 | A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone i... | 2019-01-10 | due-trials |
| Reported results | 2017-001148-37 | A randomized, double-blind (sponsor unblind), placebo-controlled, multi-centered phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen rec... | 2019-11-19 | due-trials |
| Reported results | 2017-001149-28 | A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (bude... | 2019-03-14 | due-trials |
| Reported results | 2017-001150-33 | A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (bude... | 2019-03-18 | due-trials |
| Reported results | 2017-001190-16 | A Phase IV, 12 week, randomised, double-blind, double-dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with tiotropium monotherapy based ... | 2019-07-17 | due-trials |
| Reported results | 2017-001220-22 | A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in a... | 2020-11-16 | due-trials |
| Reported results | 2017-001356-59 | A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 15 years after the first booster immunization with Encepur Adults (Polygeline-free Tick-borne Encephalitis vaccin... | 2022-03-08 | due-trials |
| Ongoing | 2017-001366-14 | A long-term safety and efficacy follow-on study in participants with transfusion dependent β-thalassemia who have previously received GSK2696277 (autologous hematopoietic stem cells genetically modifi... | not-yet-due | |
| Exempt | 2017-001452-55 | A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologica... | not-yet-due | |
| Trial is outside EEC, and reported results | 2017-001514-29 | A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents | bad-data | |
| Trial is outside EEC, and reported results | 2017-001515-36 | Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study | bad-data | |
| Trial is outside EEC, and reported results | 2017-001516-11 | 201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult... | bad-data | |
| Ongoing | 2017-001532-19 | A randomised open-label study to compare the effectiveness of the fixed dose combination of FF/UMEC/VI (using the Connected Inhaler System) with the combination of FP/SAL plus tiotropium (without the ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2017-001574-42 | A randomized, open-label, comparative study to evaluate an intermittent dosing regimen of fluticasone propionate 0·05% cream (twice per week) in reducing the risk of relapse when added to regular dail... | bad-data | |
| Trial is outside EEC, and reported results | 2017-001575-23 | Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese Subjects. | bad-data | |
| Exempt, with results | 2017-001584-20 | A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-seaso... | 2020-09-15 | not-yet-due |
| Trial is outside EEC, and reported results | 2017-001607-80 | An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis vaccine Poliorix administered as a three-dose primary vaccinat... | bad-data | |
| Trial is outside EEC, and reported results | 2017-001608-32 | An open-label study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis Vaccine Poliorix administered as a booster dose at 18-24 months of age in healthy ... | bad-data | |
| Reported results | 2017-002265-21 | A placebo-controlled, double-blind (sponsor open), randomised, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough | 2018-10-08 | due-trials |
| Reported results | 2017-002266-45 | An open label, randomised, parallel group clinical study to evaluate the effect of the Connected Inhaler System (CIS) on adherence to Relvar/Breo ELLIPTA therapy, in asthmatic subjects with poor contr... | 2019-01-24 | due-trials |
| Completed, but no date, and reported results Terminated | 2017-002268-42 | A randomized, repeat dose, open label, parallel group, multi-center study to evaluate the effect of daprodustat compared to darbepoetin alfa on forearm blood flow in participants with anemia of chroni... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-002270-39 | A 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chr... | 2020-10-07 | bad-data |
| Exempt | 2017-002574-39 | Ancillary study evaluating ChAd155-hIi-HBV shedding in a subset of chronic hepatitis B patients enrolled in the first-time-in-human, Phase I/II, randomised, multi-centric, single-blind study TH HBV VV... | not-yet-due | |
| Reported results | 2017-002919-33 | Phase IV, open-label, randomized study to enrol healthy adult volunteers, naïve to any previous meningococcal vaccination or meningococcal disease, aged 18-50 years, to be either vaccinated with GSK M... | 2022-05-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002941-31 | A Phase 2, randomised, observer-blind, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' GSK3277511A investigational vaccine when administered intramuscu... | 2020-06-03 | bad-data |
| Trial is partly outside EEC, and reported results | 2017-003456-23 | A phase 2b, randomized, controlled, observer-blind, multi-center study to evaluate safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536... | 2020-08-17 | bad-data |
| Reported results | 2017-003544-20 | A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma with... | 2020-01-06 | due-trials |
| Reported results | 2017-003692-61 | A phase 2b, randomized, controlled, observer-blind, multi-center, non-inferiority immunogenicity and safety study of two formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK35368... | 2020-02-11 | due-trials |
| Ongoing | 2017-004350-42 | Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | not-yet-due | |
| Reported results | 2017-004369-29 | The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGYTM ELLIPTATM) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Pat... | 2019-10-10 | due-trials |
| Reported results | 2017-004372-56 | A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pharma... | 2020-06-19 | due-trials |
| Reported results | 2017-004564-35 | A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Participant... | 2018-12-06 | due-trials |
| Other | 2017-004689-93 | A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalid... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004810-25 | A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More ... | 2022-03-31 | bad-data |
| Reported results | 2017-005128-12 | A Phase II, Randomized, Open-label, Multicenter Study to Assess the Immunogenicity and Safety of GSK Meningococcal MenABCWY Vaccine, and of GSK Meningococcal Group B and MenACWY Conjugate Vaccines Adm... | 2019-07-05 | due-trials |
| Other | 2018-000413-20 | A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Non-mucino... | not-yet-due | |
| Exempt, with results | 2018-000431-27 | A Phase 1/2, randomized, observer-blind, controlled, multi-center study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vacc... | 2021-11-16 | not-yet-due |
| Exempt, with results | 2018-000849-38 | A Phase I/II, randomized, placebo-controlled, observer-blind, multicenter study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational respiratory syncytial viru... | 2021-02-23 | not-yet-due |
| Ongoing, reported early | 2018-001316-29 | A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants | not-yet-due | |
| Exempt, with results | 2018-001340-62 | A study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational unadjuvanted RSV maternal vaccine compared to placebo when administered to healthy non-pregnant wo... | 2019-09-06 | not-yet-due |
| Ongoing | 2018-001540-56 | A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and charac... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-001780-23 | A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomp... | 2023-10-10 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001801-98 | A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in... | 2022-11-30 | bad-data |
| Trial is outside EEC, and reported results | 2018-001986-18 | A phase III, observer-blind, randomized, multi-country study to assess the reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK’s oral live attenuated human rotavir... | bad-data | |
| Reported results | 2018-002816-29 | A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Multiple Myeloma (DRE... | 2022-07-18 | due-trials |
| Reported results | 2018-002977-24 | A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to 80... | 2021-08-13 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-003278-28 | A multicentre randomized, double-blind (sponsor open), placebo-controlled Phase 2 study to evaluate the safety, tolerability, efficacy, dose-response, pharmacokinetics and pharmacodynamics of repeat d... | 2021-05-17 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-003949-42 | A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in C... | 2022-11-04 | bad-data |
| Other | 2018-003993-29 | DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the C... | not-yet-due | |
| Other | 2018-004252-38 | A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with R... | not-yet-due | |
| Ongoing | 2018-004354-21 | A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bo... | not-yet-due | |
| Other | 2018-004645-16 | A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy i... | not-yet-due | |
| Ongoing | 2018-004888-31 | Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor Follow-up a lungo termine dei partecipanti esposti a GSK337779... | not-yet-due | |
| Ongoing, reported early | 2019-000415-87 | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1... | not-yet-due | |
| Other | 2019-000607-33 | A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-000797-39 | A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with moder... | 2022-08-16 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000867-26 | A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in parti... | 2023-01-18 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000868-18 | A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in partic... | 2022-02-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000878-30 | A multi-centre long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis. | 2023-02-24 | bad-data |
| Other | 2019-001138-32 | A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Balantamab Mafodotin GSK2857916 as Monotherapy and in Combination with Anti-Cancer Treatments in Participants w... | not-yet-due | |
| Other | 2019-001576-11 | A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced En... | not-yet-due | |
| Ongoing | 2019-001588-63 | An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonate... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2019-001666-15 | A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to health... | 2022-09-13 | bad-data |
| Reported results | 2019-001699-12 | An open-label, randomized three period cross-over relative bioavailability study to compare the pharmacokinetic parameters of a lower dose formulation of ambrisentan (GSK1325760) with marketed ambrise... | 2019-12-17 | due-trials |
| Ongoing | 2019-001815-21 | A phase IIIB, open label, long term follow-up study to assess persistence of immune responses to GSK’s HZ/su vaccine 4-7 years after primary vaccination; and immunogenicity and safety assessment of re... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001991-12 | A Phase II, randomised, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigationa... | 2021-05-14 | bad-data |
| Reported results | 2019-002258-22 | Phase II randomized, observer-blind, placebo-controlled, multi-country study in healthy non-pregnant women 18-45 years of age to evaluate the safety, reactogenicity and immunogenicity of a 1st intramu... | 2021-11-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-002263-99 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamo... | 2023-06-20 | bad-data |
| Reported results | 2019-002988-10 | A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK's Infanrix hexa (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV's Vaxelis (DTaP5-HBV-IPV... | 2022-12-15 | due-trials |
| Ongoing | 2019-003047-30 | A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in P... | not-yet-due | |
| Other | 2019-003158-10 | Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003981-42 | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinu... | 2023-09-19 | bad-data |
| Ongoing | 2019-004680-51 | A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different ... | not-yet-due | |
| Trial is outside EEC | 2019-004982-42 | A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously pr... | bad-data | |
| Reported results | 2020-000553-27 | A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in... | 2022-12-01 | due-trials |
| Reported results | 2020-000692-21 | A phase 2b, open-label, multi-center, extension study to evaluate the safety and immunogenicity of a revaccination dose of the RSVPreF3 older adults (OA) investigational vaccine administered intramusc... | 2021-10-25 | due-trials |
| Ongoing | 2020-000753-28 | A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination of GSK's RSVPreF3 OA investigational vaccine in ad... | not-yet-due | |
| Trial is outside EEC | 2020-000972-38 | A Phase III, observer-blind, randomized, multicenter study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Rotarix Porcine circovirus (PCV)-free liquid as c... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001083-29 | Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear) | 2022-03-18 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-001355-40 | A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 ... | 2023-09-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-001759-42 | A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. | 2021-08-16 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-002000-39 | B-Fine: An open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in patients with Chronic Hepatitis B via intrahepatic immunophenotyping | 2023-11-30 | bad-data |
| Other | 2020-002202-20 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease... | not-yet-due | |
| Other | 2020-002327-11 | A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | not-yet-due | |
| Other | 2020-002359-39 | A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS | not-yet-due | |
| Ongoing | 2020-002667-53 | An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit fr... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-002979-35 | A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic ... | 2023-02-17 | bad-data |
| Other | 2020-003433-37 | A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAVE P... | not-yet-due | |
| Ongoing | 2020-003611-10 | A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe... | not-yet-due | |
| Ongoing | 2020-003612-28 | A 52-week, randomised, double-blind, double-dummy, parallel group,multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adole... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-003632-25 | A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe... | 2023-11-23 | bad-data |
| Ongoing | 2020-003973-23 | A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants with Either HER2-Negative BRCA--Mutated or Triple-Negative Breast Cancer with Molecu... | not-yet-due | |
| Other | 2020-004334-38 | A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenot... | not-yet-due | |
| Trial is partly outside EEC | 2020-004741-37 | A Phase I/II, observer-blind, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I)... | bad-data | |
| Ongoing | 2021-000007-21 | A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with p... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-000357-26 | A Phase III, observer-blind, randomized, multi-country study to evaluate the lot-to-lot consistency of GSK’s investigational RSV maternal vaccine and the immune response, safety and reactogenicity of ... | 2022-06-06 | bad-data |
| Ongoing | 2021-000554-26 | A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received... | not-yet-due | |
| Exempt | 2021-000891-12 | A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S... | not-yet-due | |
| Other | 2021-000933-15 | A 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome. Estudio abierto, de un solo grup... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2021-000994-96 | A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in high ... | 2023-05-30 | bad-data |
| Ongoing | 2021-001367-24 | A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants. | not-yet-due | |
| Other | 2021-001670-33 | A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | not-yet-due | |
| Trial is partly outside EEC | 2021-002013-34 | An Integrated Pharmacokinetic and Safety Open-label Basket Trial of Daprodustat for the Treatment of Anemia Associated with Chronic Kidney Disease in Male and Female Children and Adolescents Aged 3 Mo... | bad-data | |
| Reported results | 2021-002225-18 | A phase 3, randomized, double-blind, multi-country study to evaluate consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA investigational vaccine administrated as a single dose in adults a... | 2022-06-30 | due-trials |
| Other | 2021-003567-10 | A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleo... | not-yet-due | |
| Exempt | 2021-003586-35 | A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV vaccine in healthy participants aged 18-40... | not-yet-due | |
| Completed, reported early | 2021-003717-18 | An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab ... | 2023-06-14 | not-yet-due |
| Completed, but no date, and reported results Terminated | 2021-004003-41 | A Phase III, randomized, open-label, active vaccine-controlled crossover study to evaluate the reactogenicity, safety and immune response of unadjuvanted RSV maternal vaccine in healthy non-pregnant g... | bad-data | |
| Other | 2021-004151-16 | A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants... | not-yet-due | |
| Ongoing | 2021-005037-16 | A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (dep... | not-yet-due | |
| Ongoing | 2021-005055-36 | A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-2 (de... | not-yet-due | |
| Ongoing | 2021-005115-32 | A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Programm... | not-yet-due | |
| Other | 2021-005139-22 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatit... | not-yet-due | |
| Exempt | 2021-005178-25 | A Phase 1/2a, observer-blind, randomized, controlled, two-stage, multi-country study to evaluate the safety, reactogenicity, and immune response of the trivalent vaccine against invasive nontyphoidal ... | not-yet-due | |
| Other | 2021-005319-30 | A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune... | not-yet-due | |
| Ongoing | 2021-005392-39 | OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3... | not-yet-due | |
| Exempt | 2021-005629-25 | A Phase 1/2a, open-label, randomised, controlled, multi-country, dose-escalation study to assess the safety and immunogenicity of AS37 in combination with the Hepatitis B surface antigen (HBsAg), acco... | not-yet-due | |
| Ongoing | 2021-005692-39 | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) | not-yet-due | |
| Ongoing | 2021-005726-15 | A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with re... | not-yet-due | |
| Exempt | 2021-006215-29 | A Phase I/II, observer-blind, randomised, placebo-controlled study to assess safety, immunogenicity and efficacy of GSK S. aureus candidate vaccine when administered to healthy adults (dose-escalation... | not-yet-due | |
| Exempt | 2022-000090-15 | A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety and immunogenicity of investigational adjuvanted human papillomavirus vaccine in females (16 to 26 years of age) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2022-000623-21 | A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of an RSVPreF3 OA investigational vaccine when co-administered with FLU ... | 2023-07-17 | bad-data |
| Trial is outside EEC | 2022-000708-36 | A phase III, open-label, randomized, controlled study to evaluate the immunogenicity and safety of inactivated poliovirus vaccine (IPV) when co-administered with Porcine circovirus (PCV)-free liquid f... | bad-data | |
| Trial is partly outside EEC | 2022-001910-21 | A phase II, observer-blind, randomized, controlled study to evaluate the immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax, as a first dose, administered in h... | bad-data | |
| Ongoing | 2022-001981-36 | A Phase 3, observer-blind, randomized, placebo controlled study to evaluate the non inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of ag... | not-yet-due | |
| Other | 2022-002268-53 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatit... | not-yet-due | |
| Ongoing | 2022-002538-14 | 17 beta-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Ad... | not-yet-due | |
| Other | 2022-003124-41 | A Phase 3b, non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV MAT... | not-yet-due | |
| Other | 2022-003289-18 | A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer | not-yet-due | |
| Trial is outside EEC | 2023-000764-58 | A Phase 4, single-arm, open-label, multi-center study to assess the immune response and safety of the meningococcal Group B vaccine MenB+OMV NZ when administered to healthy infants from 2 months of ag... | bad-data | |
| Trial is outside EEC | 2023-000765-14 | A prospective, multi-center post marketing surveillance (PMS) study to monitor the safety of GlaxoSmithKline Biologicals’ SA’s (GSK) Meningococcal Group B (Bexsero) vaccine in Korean participants, whe... | bad-data |